 
 
 
 
Protocol : I5Q-MC-CGBD(d)  
  A Phase 4, Randomized, Double -Blind, Placebo -Controlled Study Evaluating 
the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult 
Participants with Epi[INVESTIGATOR_33185]  
  [STUDY_ID_REMOVED]   Approval Date: 02 -Nov-2022 
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
1 Title Page  
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_741771]  (LY2951742) , unless  such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries.  
Note to Regulatory Authorities:  This document may contain protected personal data and/or commerci ally confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries . 
Protocol Title:  A Phase 4, Randomized, Double -Blind, Placebo -Controlled Study Evaluating the 
Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants  
with Epi[INVESTIGATOR_741772]:  I5Q-MC-CGBD  
Amendment Number: d 
Compound : Galcanezumab (LY2951742)  
Brief Title: A Study to Investigate the Efficacy and Safety of Galcanezumab Versus Rimegepant 
in Adult Participants with Epi[INVESTIGATOR_741773]: 4 
Acronym: CHALLENGE -MIG  
Sponsor Name:  [CONTACT_11028]:  Indianapolis, Indiana, [LOCATION_003] [ZIP_CODE]  
Regulatory Agency Identifier Number(s)  
IND: 111295  
Approval Date:  Protocol  Amendment ( d) Electronically  Signed and  Approved  by [CONTACT_10937].  
Document ID: VV-CLIN -075435  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 [ADDRESS_1014164] Information will be provided separately . 
 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 [ADDRESS_1014165] on 
the safety or the rights of study participants . 
Overall Rationale for the Amendment:  
The purpose of this amendment is to modify the contracept ive requirements for women of child 
bearing potential.  
Section # and Name  [CONTACT_133431] n of Change  Brief Rationale  
Section 5.1 . 
Inclusion Criteria : 
Criterion 7(b) Updated the contraception 
requirements from 2 effective forms 
to single form  Modifi ed to align with recent 
internal guidance  
 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 4 Table of Contents  
1. Protocol Summary  ................................ ................................ ................................ .......... 7 
1.1. Synopsis  ................................ ................................ ................................ ............................ 7 
1.2. Schema  ................................ ................................ ................................ ............................ 10 
1.3. Schedule of Activities (SoA)  ................................ ................................ .......................... 11 
2. Introduction  ................................ ................................ ................................ ................... 16 
2.1. Study Rationale  ................................ ................................ ................................ ............... 16 
2.2. Background  ................................ ................................ ................................ ..................... 16 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 17 
3. Objectives, Endpoints, and Estimands  ................................ ................................ .......18 
4. Study Design  ................................ ................................ ................................ .................. 21 
4.1. Overall Design  ................................ ................................ ................................ ................ 21 
4.1.1.  Study Period I: Screening (Visit 1)  ................................ ................................ ................. 21 
4.1.2.  Study Period II: Prospective Baseline (Visit 2)  ................................ .............................. 21 
4.1.3.  Study Period III: Double -Blind Treatment (Visits 3 –6) ................................ ................. 22 
4.2. Scientific Rationale for Stud y Design  ................................ ................................ ............ 23 
4.3. Justification for Dose  ................................ ................................ ................................ ......23 
4.4. End of Study Definition  ................................ ................................ ................................ ..23 
5. Study Population  ................................ ................................ ................................ ........... 24 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 24 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 25 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .27 
5.4. Screen Failures  ................................ ................................ ................................ ................ 27 
5.5. Criteria for Temporarily Delaying Enrollment of a Participant  ................................ .....28 
6. Study Intervention(s) and Concomitant Therapy  ................................ ..................... 29 
6.1. Study Intervention(s) Administered ................................ ................................ ................ 29 
6.2. Preparation, Handling, Storage, and Accountability  ................................ ...................... 30 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 30 
6.4. Study Intervention Compliance  ................................ ................................ ...................... 31 
6.5. Dose Modification  ................................ ................................ ................................ .......... 32 
6.6. Continued Access to Study Intervention after the End of the 
Study  ................................ ................................ ................................ ............................... 32 
6.7. Treatment of Overdose  ................................ ................................ ................................ ...32 
6.8. Concomitant Therapy  ................................ ................................ ................................ .....32 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 34 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 34 
7.1.1.  Liver Chemistry Stoppi[INVESTIGATOR_2121]  ................................ ................................ .................. 34 
7.1.2.  QTc Stoppi[INVESTIGATOR_2121]  ................................ ................................ ................................ .....35 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ [ADDRESS_1014166] to Follow up  ................................ ................................ ................................ ............ 36 
8. Study Assessments and Procedures ................................ ................................ ............. 37 
8.1. Efficacy Assessments  ................................ ................................ ................................ .....37 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 [ADDRESS_1014167] 
Complaints  ................................ ................................ ................................ ...................... 40 
8.3.1.  Timing and Mechanism for Collecting Events  ................................ ............................... 41 
8.3.2.  Pregnancy  ................................ ................................ ................................ ........................ 42 
8.4. Pharmacokinetics  ................................ ................................ ................................ ............ 44 
8.5. Pharmacodynamics  ................................ ................................ ................................ ......... 44 
8.6. Genetics  ................................ ................................ ................................ .......................... 44 
8.7. Biomarker s ................................ ................................ ................................ ...................... 44 
8.8. Immunogenicity Assessments ................................ ................................ ......................... 44 
8.9. Health Economics  ................................ ................................ ................................ ........... 44 
9. Statistical Considerations  ................................ ................................ ............................. 45 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....45 
9.1.1.  Multiplicity Adjustment  ................................ ................................ ................................ ..45 
9.2. Analyses Sets  ................................ ................................ ................................ .................. 46 
9.3. Statistical Analyses  ................................ ................................ ................................ ......... 46 
9.3.1.  General Considerations  ................................ ................................ ................................ ...46 
9.3.2.  Primary Endpoint(s)/Estimand(s) Analysis  ................................ ................................ ....47 
9.3.3.  Secondary Endpoints/Estimands Analysis  ................................ ................................ ......47 
9.3.4.  Safety Analyses  ................................ ................................ ................................ ............... 48 
9.3.5.  Other Analyses  ................................ ................................ ................................ ................ 49 
9.4. Interim Analysis  ................................ ................................ ................................ .............. 49 
9.5. Sample Size Determination  ................................ ................................ ............................ 49 
10. Supporting Documentation and Operational Considerations  ................................ ..50 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 50 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 50 
10.1.2.  Informed Consent Process  ................................ ................................ .............................. 50 
10.1.3.  Data Protection ................................ ................................ ................................ ................ 51 
10.1.4.  Committees Structure ................................ ................................ ................................ ......51 
10.1.5.  Dissemination of Clinical Study Data ................................ ................................ ............. 52 
10.1.6.  Data Quality Assurance  ................................ ................................ ................................ ..52 
10.1.7.  Source Documents  ................................ ................................ ................................ .......... 54 
10.1.8.  Study and Site Start and  Closure  ................................ ................................ .................... 54 
10.1.9.  Publication Policy  ................................ ................................ ................................ ........... 55 
10.1.10.  Investigator Information  ................................ ................................ ................................ .55 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 6 10.2.  Appendix 2: Treatments Allowed and Treatments not Allowed as 
Concomitant Therapy  ................................ ................................ ................................ .....56 
10.3.  Appendix 3: Adverse Events and Serious Adverse Events: 
Definitions and Procedures for Recording, Evaluating, Follow -
up, and Reporting  ................................ ................................ ................................ ............ 59 
10.3.1.  Definition of AE  ................................ ................................ ................................ ............. 59 
10.3.2.  Definition of SAE  ................................ ................................ ................................ ........... 60 
10.3.3.  Recording and Follow -Up of AE and/or SAE  ................................ ................................ 61 
10.3.4.  Reporting of SAEs  ................................ ................................ ................................ .......... 63 
10.3.5.  Regulatory Reporting Requirements  ................................ ................................ ............... 63 
10.4.  Appendix 4: Clinical Laboratory Tests  ................................ ................................ ........... 64 
10.5.  Appendix 5: Liver Safety: Suggested Actions and Follow -up 
Assessments  ................................ ................................ ................................ .................... 66 
10.5.1.  Hepatic Evaluation Testing  ................................ ................................ ............................. 66 
10.5.2.  Close Hepatic Monitoring  ................................ ................................ ............................... 67 
10.5.3.  Additional Hepatic Data Collection (Hepatic Safety CRF) in 
Study Participants Who Have Abnormal Liver Tests During the 
Study  ................................ ................................ ................................ ............................... 69 
10.6.  Appendix 6: Provisions for Changes in Study Conduct During 
Exceptional Circumstances  ................................ ................................ ............................. 70 
10.7.  Appendix 7: Abbrevia tions and Definitions  ................................ ................................ ...74 
10.8.  Appendix 8: Protocol Amendment History  ................................ ................................ ....78 
11. References  ................................ ................................ ................................ ...................... 86 
 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 7 1. Protocol Summary  
1.1. Synopsis  
Protocol Title:   
A Phase 4, Randomized, Double -Blind, Placebo -Controlled Study Evaluating the Efficacy and 
Safety of Galcanezumab Versus Rimegepant in Adult Participants with Epi[INVESTIGATOR_741774]:   
A Study to Investigate the Efficacy and Safety of Galcanezumab Ver sus Rimegepant in Adult 
Participants with Epi[INVESTIGATOR_741775] : 
Identification of CGRP signaling in the pathophysiology of migraine led to the development and 
approval of 4 novel migraine -specific preventive biologics. One of these, galcanezumab, is  a 
humanized monoclonal antibody that selectively and potently binds to CGRP and prevents 
CGRP from binding to the receptor and has demonstrated efficacy in migraine prevention with a 
favorable safety profile ( Emgality package insert, 2019).  
More recently,  oral CGRP receptor antagonists, gepants, have been approved for the acute 
treatment of migraine. One of these, rimegepant, has recently been approved by [CONTACT_741795] (Nurtec ODT package insert, 2021).  
To date, there ar e no studies that have directly compared the efficacy and safety between CGRP 
antagonists in migraine prevention, creating a gap in the information needed by [CONTACT_741796].  
This study will compare the efficacy and safety of galcanezumab to rimegepant in participants 
with epi[INVESTIGATOR_17730] .  
Objectives , Endpoint s, and Estimands:  
Objectives  Endpoints  
Primary   
To assess whether galcanezumab is superior 
to rimegepant in the prevention of migraine in 
participants with epi[INVESTIGATOR_17730].  The percentage of participants with ≥50% 
reduction from baseline in monthly migraine 
headache days across the 3 -month double -
blind treatment period.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 8 Objectives  Endpoints  
Key Secondary Objectives   
If galcanezumab is statistically superior to 
rimegepant on the primary objective, the 
following key secondary objectives will be 
tested with adjustment for multiplicity:   
 To compare galcanezumab with 
rimegepant with respect to monthly 
migraine headache days.   The overall mean change from baseline in 
the number of monthly migraine headache 
days across the 3 -month double -blind 
treatment period.  
 To compare galcanezumab with 
rimegepant with respect to 75% response 
rate.  The percentage of participants with ≥75% 
reduction from baseline in monthly 
migraine headache days across the 3 -
month double -blind treatment period.  
 To compare galcanezumab with 
rimegepant with respect to monthly 
migraine headache days at:  
o Month 3  
o Month 2  
o Month 1   The mean change from baseline in the 
number of  monthly migraine headache 
days at:  
o Month 3  
o Month 2  
o Month 1  
 To compare galcanezumab with 
rimegepant with respect to migraine 
headache days with  acute (abortive) 
migraine treatment.   The overall mean change from baseline in 
the number of monthly migraine headache 
days requiring medication for the acute 
treatment of migraine or headache across 
the 3 -month double -blind treatment 
period.  
 To compare galcanezumab with 
rimegepant with respect to change in 
functioning.   The mean change from baseline in the 
Role Function -Restrictive (RF -R) domain 
score of the Migraine -Specific Quality of 
Life Questionnaire version 2.1 (MSQ 
v2.1) at Month 3.  
 To compare galcanezumab with 
rimegepant with respect to 100% response 
rate.  The percentage of participants with 100% 
reducti on from baseline in monthly 
migraine headache days across the 3 -
month double -blind treatment period.  
 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 9 Overall Design  
Study CGBD is a multi -site, randomized, double -blind, double -dummy, parallel -group, Phase 4 
study with 3 study periods in participants who  meet ICHD criteria for a diagnosis of migraine 
with or without aura with an epi[INVESTIGATOR_741776] 4 to 14 migraine headache days per month.   
Brief Summary:  
The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the 
prevention of migraine in participants with epi[INVESTIGATOR_741777] e.  
The study duration will be approxi mately  5 months . 
The treatment duration will be approximately  3 months . 
The visit frequency will be approximately monthly .  
Number of Participant s: 
Approximat ely 1150 participants will be screened to achieve a minimum of approximately 575  
randomized  study participants .  
Intervention Groups  and Duration : 
Interventions : 
 Galcanezumab 120  mg subcutaneous injection  once monthly, with a 240  mg loading dose 
as the initial dose  
 Rimegepant 75  mg oral tablet  every other day  
Participants will be given placebo in a double -dummy design.  
Data Monitoring Committee: No 
 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 10 1.2. Schema  
 
Abbreviations: ODT = oral disintegrating tablet;  QM = every month; QOD = every other day;  SC = subcutaneous . 
a Screening Period is [ADDRESS_1014168] up to 5 additional days , if needed , to schedule 
participant ’s Visit [ADDRESS_1014169] administration only.  
Note: P articipants will be given placebo in a double -dummy design .  
 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 11 1.3. Schedule of Activities  (SoA)  
SP I – Screening  
Visit 1 procedures may be conducted over more than 1 day as long as all 
activities are completed within the allowable visit tolerance.  SP II  – 
Prospective 
Baseline  SP III  – Double -Blind 
Treatment  ET Comments  
Visit  Number  1 2 3 4a 5a 6   
Month relative to randomization (V3)  * **  1 2 3  *Screening lasts from 3 to 30 days.  
** Eligibility is determined between a minimum of [ADDRESS_1014170] up to 5 additional 
days, if needed , to schedule participant ’s Visit 3 
appointment.  
For scheduling purposes, a month is 30 days.  
Interval allowance (days)    - ±2 ±2 ±[ADDRESS_1014171] be signed before any protocol -specific tests or 
procedures are performed.  
Inclusion and exclusion , review and confirm  X X X      
Demographics  X        
Medical history  X        
Substance use  X       Substances: alcohol, caffeine, nicotine, tobacco  
Concomitant med ication s X X X X X X X  
AE X X X X X X X Any events that occur after signing the ICF are considered AEs 
as defined in Section 10.3. 
Physical Evaluation  
Height  X        
Weight  X        
12-lead ECG (local)  X     X X ECGs should be collected prior to blood draws. Participant s 
should be supi[INVESTIGATOR_17044] 5 to 10 minutes before 
ECG collections and remain supi[INVESTIGATOR_170245].  
See Section 8.2.3  for additional details.  
Vital signs  X  X   X X Includes body temperature, sitting blood pressure, and pulse.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 12 SP I – Screening  
Visit 1 procedures may be conducted over more than 1 day as long as all 
activities are completed within the allowable visit tolerance.  SP II  – 
Prospective 
Baseline  SP III  – Double -Blind 
Treatment  ET Comments  
Visit  Number  1 2 3 4a 5a 6   
Month relative to randomization (V3)  * **  1 2 3  *Screening lasts from 3 to 30 days.  
** Eligibility is determined between a minimum of [ADDRESS_1014172] up to 5 additional 
days, if needed , to schedule participant ’s Visit 3 
appointment.  
For scheduling purposes, a month is 30 days.  
Interval allowance (days)    - ±2 ±2 ±[ADDRESS_1014173] -menopausal status  in 
women aged 40 to 55 (inclusive)  as outlined in footnote c. 
Additional pregnancy tests (beyond those required per the 
SoA) should be performed at any time during the trial if a 
menstrual period is missed, there is clinical suspi[INVESTIGATOR_81178], or as required by [CONTACT_51967].  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 13 SP I – Screening  
Visit 1 procedures may be conducted over more than 1 day as long as all 
activities are completed within the allowable visit tolerance.  SP II  – 
Prospective 
Baseline  SP III  – Double -Blind 
Treatment  ET Comments  
Visit  Number  1 2 3 4a 5a 6   
Month relative to randomization (V3)  * **  1 2 3  *Screening lasts from 3 to 30 days.  
** Eligibility is determined between a minimum of [ADDRESS_1014174] up to 5 additional 
days, if needed , to schedule participant ’s Visit 3 
appointment.  
For scheduling purposes, a month is 30 days.  
Interval allowance (days)    - ±2 ±2 ±[ADDRESS_1014175] 
conducted . 
Scales, Questionnaires, and Outcome Measures  
ePRO and headache medication log training   X       
ePRO daily diary   Participant completes daily   
Headache medication log (paper)   The participant records the date, name, dose, and number of acute 
medications taken  The headache medication log should be returned to site staff at 
the final office visit or ET visit.  
Collect ePRO diary and paper headache 
medication log       X X  
Participant training video (participation in a 
clinical trial)   X     Videos may be viewed at either V2 or V3 . 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 14 SP I – Screening  
Visit 1 procedures may be conducted over more than 1 day as long as all 
activities are completed within the allowable visit tolerance.  SP II  – 
Prospective 
Baseline  SP III  – Double -Blind 
Treatment  ET Comments  
Visit  Number  1 2 3 4a 5a 6   
Month relative to randomization (V3)  * **  1 2 3  *Screening lasts from 3 to 30 days.  
** Eligibility is determined between a minimum of [ADDRESS_1014176] up to 5 additional 
days, if needed , to schedule participant ’s Visit 3 
appointment.  
For scheduling purposes, a month is 30 days.  
Interval allowance (days)    - ±2 ±2 ±2   
Telephone Visit     X X   See footnote a.  
Participant training video (self -injection of 
study intervention)   X     
MSQ v2.1    X   X X Participant -rated assessments completed onsite should be 
completed prior to administration of study intervention and 
clinical examination .  MIDAS    X   X X 
PGI-S   X   X X 
Randomization and Dosing  
Randomization    X      
Study intervention administration at site (SC 
and ODT)    X     Study intervention will be administered  by [CONTACT_741797] V3 (both SC and ODT ) after all ot her visit 
procedures are completed . 
Dispense study intervention and ancillary 
supplies    X     Study intervention is dispensed by [CONTACT_741798] . 
Administration of ODT study intervention at 
home     X  Participants  will self -administer their ODT every other day at 
home.  
Administration of SC study intervention at 
home     X X   Participant s to se lf-administer the SC study intervention at 
home prior to  the telephone visit with the study site . 
Return unused study intervention and ancillary 
supplies       X X Return any unused study intervention in the ancillary 
containers to unblinded site personnel.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 15 Abbreviations: AE = adverse event; ECG = electrocardiogram; ePRO = electronic patient -reported outcomes; ET = early termination; FSH = follicle stimulating 
hormone;  ICF = informed consent form ; MIDAS = Migraine Disability Assessment; MSQ v2.1 = Migraine -Specific Quality of Life Questionnaire vers ion 
2.1; ODT  = orally disintegrating tablet ; PGI-S =Patient Global Impression of Severity;  SC = subcutaneous ; SP = study period; UDS = urine drug screen; V = 
visit; WOCBP = woman of childbearing potential.  
aVisit s 4 and 5 are to confirm/assess the following: administration of study intervention prior to the telephone call; WOCBP completed a urine pregnancy test 
prior to administration of study intervention; and collection/ review spontaneously reported AEs and concomitant medicatio ns. Participants to be  reminde d to 
complete the ePRO diary daily  and record any acute migraine medication use into the headache medication log . 
bSelected tests may be obtained in the event of a treatment -emergent hepatic abnormality and may be required in follow -up with participant s in consultation with  
Lilly, or its designee. See Section 10.[ADDRESS_1014177] -menopausal status at V2 in women aged 40 to 55 (inclusive) with an intact uterus, not on hormone therapy, who has had 
cessation of menses for at least 12 consecutive months without an alternative medical cause , AND with a n FSH >40 mIU/mL . 
 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 16 2. Introduction  
2.1. Study Rationale  
Identification of CGRP signaling in the pathophysiology of migraine led to the development and 
approval of 4 novel migraine -specific preventive biologics . One of these, g alcanezumab, is a 
humanized monoclonal antibody that selectively and potently binds to CGRP and prevents 
CGRP from binding to the receptor  and has demonstrated efficacy  in migraine prevention  with a 
favorable safety profile  (Emgality package insert , 2019) . 
More recently,  oral CGRP  receptor  antagonists, gepants, have been approved for the acute 
treatment of migraine. One of these, rimegepant , has recently been approved by [CONTACT_741799][INVESTIGATOR_17730]  (Nurtec ODT package insert , 2021).  
To date, there are no studies that have directly compared the efficacy and safety between CGRP 
antagonists in migraine prevention, creating a gap in the information needed by [CONTACT_741800] s to make informed decisions reg arding their treatment.  
This study will compare the efficacy and safety of galcanezumab to rimegepant in participants 
with epi[INVESTIGATOR_17730] .  
2.2. Background  
Migraine is a chronic, debilitating condition that is the second highest cause of disability 
worldwid e (Vos et al . 2017) , and is associated with a substantial impact on the participant ’s 
quality of life and ability to work ( Leonardi and Raggi  2019). Guidelines recommend preventive 
treatment in participant s with more than 3 days  per month  of headache -related disability ( Lipton 
and Silberstein 2015 ). 
CGRP is a potent vasodilator (Brain et al. 1985)  with well-established roles in neurogenic 
inflammation and nociception (Hirsch et al. 2013)  and has been established as a valid therapeutic 
target in migrain e (Chiang and Schwedt 202 0). Early studies suggesting a role of CGRP in 
migraine  showed  increased plasma or serum levels of CGRP  during migraine attack s (Goadsby 
[CONTACT_2297]. 1990; Goadsby [CONTACT_529987] 1993; Juhasz  et al. 2003; Juhasz  et al. 2005 ). Additionally, 
CGRP infusion was shown to induce migraine attacks that were indistinguishable from a 
spontaneous attack in individuals with migraine (Lassen et al. 2002; Hansen et al. 2010) . 
Subsequent ly, studies demonstrated  that inhibition of CGRP signali ng was efficacious i n 
reducing the frequency of  migraine  (Charles and Pozo -Rosich 2019 ).  
The efficacy and safety of galcanezumab, a humanized monoclonal antibody that potently and 
selectively binds to CGRP  to prevent CGRP -mediated biological effects , has been established in 
several clinical trials in epi[INVESTIGATOR_33176], including 2 placebo -controlled, Phase 3 
clinical trials for preventive treatment in epi[INVESTIGATOR_17730] ( Skljarevski et al. 2018; Stauffer 
et al. 2018) .  
In addition, the efficacy and safety of rimegepant, a small molecule oral CGRP  receptor  
antagonist, has been evaluated in a Phase 2/3 study for preventive treatment of migraine  (Croop  
et al. 2021 ). 
No data are currently available t hat directly compare galcanezumab with an oral  CGRP  
antagonist in a clinical s tudy. This study will evaluate galcanezumab and rimegepant using the 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 17 same endpoints  in the same clinical setting  and will provide  important information to clinicians 
when making treatment decisions for their participant s. 
2.3. Benefit /Risk Assessment  
More detailed information about the known and expected benefits and risks and reasonably 
expected  AEs of galcanezumab  may be found in the IB and USPI (Emgality package insert , 
2019). 
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of rimegepant may be found in the Package Insert (Nurtec ODT package insert , 
2021).  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 18 3. Objectives , Endpoints , and Estimands  
Objectives  Endpoints  
Primary   
To assess whether galcanezumab is superior 
to rimegepant in the prevention of migraine in 
participants with epi[INVESTIGATOR_17730].  The percentage of participant s with ≥50% 
reduction from baseline in monthly migraine 
headache days across the 3 -month double -
blind treatment period . 
Key Secondary Objectives   
If galcanezumab is statistically superior to 
rimegepant on the primary objective, the 
following key secondary objectives will be 
tested  with adjustment for multiplicity :  
 To compare galcanezumab with 
rimegepant with respect to monthly 
migraine headache days .  The overall mean change from baseline in 
the number of monthly migraine headache 
days across the 3 -month double -blind 
treatment period . 
 To compare galcanezumab with 
rimegepant wi th respect to 75% response 
rate.  The percentage of participant s with ≥75% 
reduction from baseline in monthly 
migraine headache days across the 3 -
month double -blind treatment period . 
 To compare galcanezumab with 
rimegepant with respect to monthly 
migraine headache days at :  
o Month 3  
o Month 2  
o Month 1   The mean change from baseline in the 
number of monthly migraine headache 
days at :  
o Month 3  
o Month 2  
o Month 1  
 To compare galcanezumab with 
rimegepant with respect  to migraine 
headache days with  acute (abortive) 
migraine treatment .  The overall mean change from baseline in 
the number of monthly migraine headache 
days requiring medication for the acute 
treatment of migraine or headache across  
the 3 -month double -blind treatment 
period . 
 To compare galcanezumab with 
rimegepant with respect to change in 
functioning .  The mean change from baseline in the 
Role Function -Restrictive (RF -R) domain 
score of the Migraine -Specific Quality of 
Life Questionnaire version 2.1 (MSQ 
v2.1) at Month 3 . 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 19 Objectives  Endpoints  
 To compare galcanezumab with 
rimegepant with respect to 100% response 
rate.  The percentage of participant s with 100% 
reduction from baseline in monthly 
migraine headache days across the [ADDRESS_1014178] to changes in disability and 
health -related quality of life . 
 Changes from baseline to Month 3 on the 
following measures:  
 MSQ v2.1 total score, and Role 
Function -Preventive (RF -P) and  
Emotional Function (EF) domain 
scores  
 MIDAS (Migraine Disability 
Assessment) total score  
To describe  the safety and tolerability of 
galcanezumab and rimegepant.   Analysis of:  
o treatment -emergent adverse events 
(TEAEs)  
o serious adverse events (SAEs)  
o discontinuation due to adverse events 
(AEs)  
o discontin uation rates  
o vital signs  
o laboratory measures  
Tertiary/Exploratory   
To compare galcanezumab with rimegepant 
with respect to change in participant  global 
impression of the severity of migraine . Mean change from baseline in the Patient 
Global Impression of  Severity (PGI -S) at 
Month [ADDRESS_1014179] to change in Total Pain Burden.  Mean change from baselin e in the Monthly 
Total Pain Burden across the 3 -month double -
blind treatment period . 
 
  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 20 Migraine and Headache Endpoint Definitions:  
Diagnosis  Definition/Criteria  
Migraine headache  A headache, with or without aura, of ≥30 minutes duration,  with both of the 
following required features (A and B) : 
A. At least 2 of the following headache characteristics:  
 Unilateral location  
 Pulsating quality  
 Moderate or severe pain intensity  
 Aggravation by [CONTACT_741801]  
B. During headache at least 1 of the following:  
 Nausea and/or vomiting  
 Photophobia and phonophobia  
(Definition adapted from the standard IHS ICHD -3 definition)  
Probable migraine headache  A headache of ≥[ADDRESS_1014180] 1 B criteria.  
Migraine heada che day 
(primary objective)  A calendar day on which a migraine headache or probable migraine headache 
occurs.  
Migraine headache attack  Beginning on any day a migraine headache or probable migraine headache is 
recorded and ends when a migraine -free day occ urs. 
Non-migraine headache  All headaches of ≥30 minutes duration not fulfilling the definition of migraine 
or probable migraine .  
Non-migraine headache day  A calendar day on which a non -migraine headache occurs.  
Headache day  A calendar day on which any type of headache occurs (including migraine, 
probable migraine, and non -migraine headache).  
Abbreviations : ICHD = International Classification of Headache Disorders; IHS = International Headache Society.  
 
Primary estimand/coprimary estimand  
See Section s 9.3.2  and 9.3.3  for estimands.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 21 4. Study Design  
4.1. Overall  Design  
Study CGBD is a multi -site, randomized, double -blind, double -dummy, parallel -group , Phase 4 
study with 3 study periods in participant s who meet IHS-ICHD -3 (2018 ) criteria for a diagnosis 
of migraine with or without aura with an epi[INVESTIGATOR_741776] 4 to 14 migraine headache days 
per month.  
Interventions : 
 Galcanezumab 120 mg SC once monthly, with a 240  mg loading dose as the initial dose  
 Rimegepant [ADDRESS_1014181] ration  of study interventions 
(galcanezumab, rimegepant , and respective placebo). The designated unblinded site personnel 
are also responsible  for recording  information in the Study Drug Administration  Log and 
confirming treatment assignments.
Unblinded site personnel will not be involved in participant  screening, enrollment, and 
assessment of efficacy or safety. It is critical that the blind is maintained throughout the study (3 
months).  
4.1.1.  Study Period I: Screening  (Visit 1)  
At Visit 1:  
 The study and potential risks will be explained to the participant.  
 The ICF must be signed before any study procedures are performed.  
 A full clinical assessment (including a comprehensive medical evaluation documenting 
medical history, and a physical and neurological examination [see SoA, Section 1.3]).  
Visit [ADDRESS_1014182] scheduled procedure of 
the screening assessment for the participant is completed. Participants  are required to discontinue 
all excluded medications (see Sections 5, 6.8 and 10.2). 
Qualified participants will enter Study Period II (prospective baseline; Section 4.1.2 ) to 
determine their eligibility for the study ( Inclusion Criteria #4 and #5) and to establish baseline 
data for comparison of endpoints during the treatment period.  
4.1.2.  Study Period II: Prospective Baseline  (Visit 2)  
At Visit 2:  
 Participants are to be set -up and trained on their ePRO diary and instructed to begin 
logging in daily (beginning the day of Visit 2) to the ePRO diary to answer questions 
about the occurrence of  
o headaches,  
o headache duration,  
Approved on 02 Nov 2022 GMT
CCI
CCI
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 22 o headache features,  
o severity of headache, and  
o whether  any acute headache medication was taken.  
 Participants will record the name, dose, and date of any acute headache medication on a 
separate paper headache medication log.  
NOTE: The headache medication log  should  be returned to site staff at the final office 
visit or early termination visit.  
Processing of Visit 2 in IWRS triggers the initial shipment of study intervention ; therefore , 
ensure V isit 2 is completed in IWRS promptly . 
Sites will be notified via an eligi bility report whether the participant met criteria and are eligible 
to be randomized at Visit 3 (See Section 4.1.3 ). Eligibility is assessed  beginning on Day [ADDRESS_1014183] up to 5 
additional days if needed to schedule participant ’s Visit [ADDRESS_1014184] not be told the number of m igraine headache 
days on which study qualification is based.  
At either Visit 2 or Visit 3 : 
 If available and where local regulations and Ethical Review Boards allow, participants 
will also watch two training videos  
o Video 1: is designed to address participant expectation with regards to 
participation in trial which includes placebo and the difference between medical 
treatment and research  
o Video 2: self -injection of SC study intervention video  
NOTE: If the participant watched the video at Visit 2, th ey do not need to watch the 
video again at Visit 3. However, if the participant watched [ADDRESS_1014185] watch the remaining video at Visit 3.  
4.1.3.  Study Period III: Double -Blind Treatment  (Visits 3–6) 
At Visit 3:   
 Participants meeting all eligibility requirements will be randomized in a 1:1 ratio to 
receive either galcanezumab subcutaneously or rimegepant ODT.  
o A participant will be considered enrolled in the study when randomization occurs. 
To preserve blinding thr oughout the study, each treatment group will receive both 
SC injection(s) monthly and an ODT every other day, as described in Section 6.1. 
 Participant s receive first dose of study intervention as the last procedure of Visit 3.  
o The participant (or caregiver) will also be appropriately trained in how to 
administer SC injection and take the orally dissolving tablet. All  participants will 
receive:  
▪ 2 SC injections of study intervention (2 galcanezumab injections of 
120 mg or 2 placebo injections), and  
▪ 1 ODT of study intervention (rimegepant 75  mg ODT or placebo ODT).  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 23 After Visit 3  
The monthly SC injections of study intervention  will be administered  by [CONTACT_741802], but prior to, the scheduled telephone visits (Visits 4 and  5). Similarly, 
after Visit 3, participants will self -administer the ODT study intervention every other day.  
Visit [ADDRESS_1014186] scheduled 
office visit (Visit 6  [approximately 90 days after Visit 3 ]) or early termination.   
Participants will continue to log in and complete the  ePRO diary each day.  
Participants may continue to take their allowed acute migraine headache medication (with some 
limitations; see Section 6.8 and 10.2) during the treatment period and will continue to record this 
use in the headache medication log.  
4.2. Scientific Rationale for Study Design  
This study will examine the effect of galcanezumab versus rimegepant in participants with 
epi[INVESTIGATOR_17730] .  
The length of the randomized,  parallel,  double -blind treatment period  (3 months) is considered a 
sufficient duration to demonstrate the efficacy of a migraine preventive medication, given the 
validated mechanism in migraine prevention and observed onset of action for the CGRP 
antagonists , including galcanezumab  and rimegepant  (Dodick et al. 2014a, 2014b ; Schwedt et al. 
2018 ; Croop et al. 2021 ; Kuruppu  et al. 2021 ). 
The primary endpoint , 50% or greater reduction in monthly migraine headache day s, was 
selected as it is a direct and clinically relevant measure, and it provides a reliable and valid 
measurement of the intended treatment effect  (AHS 2019) . 
4.3. Justification for Do se 
The galcanezumab dosing regimen used in this study is the approved dos e for the treatment of 
migraine in  adults (Emgality package insert , 2019).  
The rimegepant dosing regimen used in this study is the approved dose for the preventive  
treatment of epi[INVESTIGATOR_338941] (Nurtec ODT package insert , 2021).  
4.4. End of Study  Definition  
The end of the study is defined as the date of last scheduled procedure shown in the SoA for the 
last participant in the trial.  
A participant is considered to have compl eted the study if the participant  has completed all 
periods  of the study including the last scheduled procedure shown in the SoA. 
 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 24 5. Study Population  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Participant must be 18 to 75 years of age (inclusive ) at the time of signing the informed 
consent.  
Type of Participant and Disease Characteristics  
2. Have a diagnosis of migraine as defined by [CONTACT_41997] -3 guidelines (1.1 or 1.2) (ICHD -3 
2018), with a history of migraine headaches of at least [ADDRESS_1014187] 3 mont hs. 
4. From Visit 2 to Visit 3 (prospective baseline period), have a frequency of [ADDRESS_1014188] 2 migraine attacks ( Section 3, Migraine and Headache 
Endpoint Definitions table ).  
To avoid biased reporting, participant s must not be told the number of migraine 
headache days on which study qualification is based.  
5. From V isit 2 to Visit 3 (prospective baseline period), must achieve sufficient compliance 
with ePRO daily headache entries as demonstrated by [CONTACT_741803] 80% of daily 
ePRO diary entries.  
Weight  
6. Body mass index (BMI) <40 kg/m2. 
Sex and Contraceptive/Ba rrier Requirements  
7. Male s and female s may participate in this trial.  
a. Males  
i. No male contraception is required except in compliance with specific local 
government study requirements . 
b. Females  
i. WOCBP  must test negative for pregnancy at Visit 1. 
ii. WOCBP  must agree to use [ADDRESS_1014189] dose of study intervention (refer to the Reference Manual  
for acceptable forms of contraception) .  
Birth control is not required if the female  is infertile due to surgical sterilization 
(examples of  surgical sterilization include  bilateral salpi[INVESTIGATOR_8936] -oophorectomy, 
bilateral salpi[INVESTIGATOR_1656] , bilateral oophorectomy, or total hysterectomy) or is post-
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 [ADDRESS_1014190] -
surgical  bilateral oophorectomy with or without hysterectomy  at any age , 
confirmed by [CONTACT_741804] e; or a cessation of menses for at least 12 consecutive 
months not induced by a medical condition or hormone therapy , and a follicle -
stimulating hormone level >40  mIU/mL in women aged [ADDRESS_1014191] uterus ; or at least [ADDRESS_1014192] any personal medical data related to the study or information related to 
the study on any website or social media site ( for example , Facebook, Twitter, LinkedIn,  
and Google+) until the entire trial has completed.  
5.2. Exclusion Criteria   
Participants are excluded from the study if any of the following criteria apply:  
Medical Cond itions  
10. Known hypersensitivity to rimegepant or galcanezumab, and their excipi[INVESTIGATOR_840], or to 
monoclonal antibodies or other therapeutic proteins.  
11. Have  local reading of ECG at Visit 1 showing abnormalities compatible with acute 
cardiovascular events and/or serious cardiovascular risk, or have had myocardial 
infarction, unstable angina, percutaneous coronary intervention, coronary artery by[CONTACT_4660], or stroke within [ADDRESS_1014193] planned cardiovascular surgery or 
percutaneous coronary angio plasty. QTcF >450  msec for males or >[ADDRESS_1014194] be discussed and judged not clinically significant by [CONTACT_28824] [INVESTIGATOR_741778].  
12. Any liver tests outside the normal r ange at Visit 1 that are clinically significant. ALT >[ADDRESS_1014195], or TBL >1. 5x ULN, or ALP > 2x ULN must be judged not clinically significant by 
[CONTACT_458] , and Lilly Medical  informed  prior to enrollment.  
13. Evidence of psychiatric disease by [CONTACT_334709], such as schizophrenia, personality 
disorders, or other serious mood or anxiety disorders.  
Note: Participant s with major depressive disorder (MDD) , an anxiety disorder , or bipolar 
disorder  whose disease state is considered stable and expected t o remain stable throughout 
the course of the study, in the opi[INVESTIGATOR_871], may be considered for inclusion 
if they are not on excluded medications.  
14. Participant s who, in the clinician’s judgment, are actively suicidal and therefore deemed to 
be at significant risk for suicide, or have had clinically significant suicidal ideation within 
the past month ( for example , includes some plan or intent to act), or have had any suicidal 
behavior within the past month.  
15. Women who are pregnant or nursing.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 [ADDRESS_1014196] an acute, serious, or unstable medical condition that, in the judgment of the 
investigator, indicates a medical problem that would preclude study participation.  
Prior/Concomitant Therapy  
17. Current use or prior exposure to any CGRP antagonist (small molecule or antibody) for 
any indication, including those who have previously completed or withdrawn from this 
study or any other study investigating a CGRP antagonist (small molecule or antibody).  
18. Are currently receiving medication  or other treatments for the prevention of migraine. 
Participant s must have discontinued such treatment at least [ADDRESS_1014197] 3 months prior to Visit 2. Nerve blocks or 
device use (such as transcranial magnetic stimulation) in the head or neck area or for 
migraine prevention must be discontinued at least 30 days prior to Visit 2.  
19. Exclusion Criterion [19] was removed.  
20. Conc omitant use of inhibitors of P -gp and BCRP are prohibited, and use of moderate or 
strong CYP3A4 inhibitors and moderate or strong CYP3A inducers is prohibited.  
21. Participant s who have used opi[INVESTIGATOR_635322] > [ADDRESS_1014198] 3 months  (opi[INVESTIGATOR_741779]) . 
22. History of drug or alcohol abuse/dependence within 1 year prior to Visit 1 (excessive or 
compulsive use as judged by [CONTACT_20616] r), or currently using drugs of abuse (including 
opi[INVESTIGATOR_2438], barbiturates, and marijuana), or any prescribed or over -the-counter medication in 
a manner that the investigator considers indicative of abuse/dependence.  
23. Have a positive urine drug screen for any substances of abuse at Visit 1.  
Note: A retest is allowed if the urine drug screen is positive for any prescribed substance 
or if, in the judgment of the investigator, there is an acceptable medical explanation fo r the 
positive result. The results of the retest must be negative at or prior to Visit 2.  
i. Participants  who have a positive urine drug screen for an amphetamine  or 
benzodiaz epi[INVESTIGATOR_741780]’s  
discretion  providing the dose of the medication is stable for at least [ADDRESS_1014199] document their determinatio n in the participant ’s source 
medical records . 
ii. Participants  who have a posi tive urine drug screen  for cannabis or cannabinoids  
which is  prescribed  (not recreation al) for a condition  other than migraine or 
headache  may be allowed in the study  provided the use is not expected to affect  
the interpretation of study results or safety of the participant . The usage should 
remain consistent for the duration of the study.  The investigator must document 
their determination in the participant ’s source medical rec ords.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 27 Prior/Concurrent Clinical Study Experience  
24. Are currently enrolled in any other clinical trial involving a study intervention  or any other 
type of medical research judged not to be scientifically or medically compatible with this 
study.  
25. Have participated within the last 30 days or within 5 half -lives (whichever is longer) in a 
clinical trial involving an investigational product. If the investigational product’s half -life 
is not known, [ADDRESS_1014200] passed prior to Visit 1.  
Diagnostic Assessments  
26. History of new daily persistent headache, cluster headache or migraine subtypes including 
hemiplegic (sporadic or familial) migraine, retinal migraine, and migraine with brainstem 
aura (basilar -type migraine) defined by [CONTACT_41997] -3. 
27. In the [ADDRESS_1014201] other types of headache in that 
time. F or instance, medication overuse headache or cluster headache.  
33. Prior to Visit 1, a history of ≥15 headache days (migraine, probable migraine or any other 
headache) per month on average during the past 3 months or are suspected of suffering 
from chronic migraine as defined per IHS ICHD -3. 
28. History of head or neck injury within 6 months prior to Visit 1.  
29. History of traumatic head injury associated with significant change in the quality or 
frequency of their headaches.  
Other Exclusions  
30. Are investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
biological or legally adopted . 
31. Are Lilly employees . 
32. In the opi[INVESTIGATOR_741781].  
5.3. Lifestyle Considerations  
Not applicable.  
5.4. Screen Failures  
A screen failure occurs when a participant  who consent s to participate in the clinical study  is not 
subsequently enrolled  in the study . A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participant s to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory 
authorities. Minimal information includes demography, screen failure details, eligibility criteria, 
and any SAE .  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 28 Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened  once  with approval from Lilly Medical for only the criteria shown below . If 
rescreen ing is performed, the participant must sign a new ICF  and will be assigned a new 
participant number .  
A participant may rescreen when sufficient time has passed for the participant to meet the 
duration requirement or condition of the following criteria during the study enrollment period:  
 Inclusion Criterion [1] (Age): if the participant is less than age 18 at the time of informed 
consent, they may be rescreened if they reach age 18  during the study enrollment period  
 Inclusion Criterion [ 7]: Negative preg nancy test  
 Exclusion Criterion [ 15]: Women who are pregnant or nu rsing  
 Exclusion Criterion [ 16]: Acute, serious, or unstable medical condition . Some patients 
may qualify for rescreen if the acute illness  resolves  or unstable conditio n is stabilized 
(e.g., uncontrolled or unstable hypertension or blood pressure)  
 Exclusion Criterion [ 18]: Washout of previous preventives for migraine headache   
 Exclusion Criterion [ 25]: Washout of previous investigational product  
 Participants who have become eli gible to enro ll in the study as a result of a protocol 
amendment  
Use of concomitant medication that requires a stable dose for a specific duration prior to Visit 2  
may be rescreened if additional time is needed to meet the duration requirement . 
In addition, after consultation with and approval by a Lilly Medical representative , a participant  
may be rescreened if there is an unexpected technical difficulty with the e PRO  diary capture 
during the prospective baseline period.  
5.5. Criteria for Temporarily Delaying Enrollment of a Participant  
Not applicable.  
 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 29 6. Study Intervention (s) and C oncomitant Therapy  
Study intervention is defined as an y investigational intervention (s), marketed product(s), 
placebo , or medical device (s) intended to be administered to /used by  a study participant 
according to the study protocol.  It is a pharmaceutical form of an active ingredient or placebo being 
tested or used as a reference in a clinical trial, including a product with a marketing authorization 
when used or assembled (formulated or packaged) in a way different from the approved form, or 
when used for an unapproved indication, or when used to gain further information about an approved 
use (FDA 2018) . 
6.1. Study Intervention(s) Administered  
Group Name  [CONTACT_741822](s)  120 mg N/A 75 mg N/A 
Dosage 
Level(s)  240 mg (2 
injection s) 
loading dose, 
then 120  mg 
monthly  1 tablet every 
other day  75 mg every 
other day 2 SC injections 
loading dose, then 
1 SC inj ection  
monthly  
Route of 
Administration  SC Oral Oral SC 
Use Experimental  
IMP and 
NIMP  IMP 
Sourcing  Provided centrally by [CONTACT_741805].  Each container will be 
labeled as required per country requirement . 
Abbreviations: IMP = investigational medicinal product; N/A = not applicable; NIMP = non -investigational 
medicinal product; ODT = orally disintegrating tablet; SC = subcutaneo us. 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 30 6.2. Preparation , Handling , Storage , and Accountability  
 The investigator or designee must confirm appropriate storage conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before u se of the study intervention.  
 Only participants enrolled in the study may receive study intervention . Only authorized 
study personnel  may supply , prepare,  or administer study intervention. All study 
intervention must be stored in a secure, environmentally controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized  study personnel . 
 The investigator  or authorized study personnel are  responsible for study intervention 
accountability, reconciliation, and record maintenance ( that is , receipt, reconciliation, and 
final disposition records).  
 The designated unblinded site personnel will handle all study intervention preparation, 
handling a nd accountability  
 
 Further guidance and information for the final disposition of unused study interventions 
are provided .  
6.3. Measures to Minimize Bias: Randomization and Blinding  
This is a randomized, double -blind, double -dummy study .  
Participants will be randomly assigned in a 1:1 ratio to receive study intervention. All 
participants will be centrally assigned to randomized study intervention using an I WRS. Before 
the study is initiated, the log in information and directions for the IWRS will be provided to each 
site. Participants will be stratified by [CONTACT_229502] (<8 migraine headache days 
versus ≥8 migraine headache days). Randomization  into [ADDRESS_1014202] possible visit interval between visits .  
Returned study intervention should not be re -dispensed to the participants.   
Treatment assignments will remain blinded to investigators, study site per sonnel directly 
involved in participant  assessments, and participants . To preserve the blinding of the study, a 
minimum  number of Lilly personnel will see the randomization table and treatment assignments 
before the  study is complete d. Designated unblinded site personnel are responsible for receipt of 
study intervention  shipments, dispensing study intervention , confirming treatment assignments , 
and receipt of any unused study interventio n by [CONTACT_2299] . Designated unblinded site 
personnel will not be involved in any clinical aspects of the study, including clinical evaluations 
and AE assessments. It is critical that the blind is maintained throughout the study (3 months).  
 
As the last procedure of V isit 3, the unblinded site personnel will train the participant /caregiver  
on SC administration, which may include injecting the contents of the first syringe and 
supervising the participant /caregiver in the administration of the second injection. The unblinded 
Approved on 02 Nov 2022 GMT
CCI
CCI
CCI
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 [ADDRESS_1014203] dose of ODT.  
At the telephone visits at which an injection is to occur , self -injections are to  occur on the same 
day as the scheduled telephone visi t, prior to the start of visit procedures.  
In the event of a quality assurance audit, the auditor(s) will be allowed ac cess to unblinded study 
intervention records at the site(s) to verify that randomization/dispensing has been done 
accurately.  
Emergency Unblinding  
This is a double -blind study in which participants, caregivers, and study site personnel who are 
performing clinical assessments are blinded to study intervention. The IWRS will be 
programmed with blind -breaking instructions. In case of an emergency, the i nvestigator has the 
sole responsibility for determining if unblinding of a participants’ intervention assignment is 
warranted.  
Participant safety must always be the first consideration in making such a determination. If the 
investigator decides that unbli nding is warranted, the investigator should make every effort to 
contact [CONTACT_1152] a participant’s intervention assignment unless this could 
delay emergency treatment for the participant. If a participant’s intervention assignment is 
unblinded, the sponsor must be notified immediately after breaking the blind.  The date and 
reason that the blind was broken must be recorded.  
If an investigator, site personnel performing assessments, or participant is unblinded, the 
participant must be di scontinued from the study. In cases where there are ethical reasons to have 
the participant remain in the study, the investigator must obtain specific approval from a sponsor 
medical monitor  for the participant to continue in the study.  
6.4. Study Intervention Compliance  
At Visit 3, the dose of study intervention and study participant identification will be confirmed 
by [CONTACT_741806]. The date and time of each dose 
administered will be recorded .  
Compliance will be assessed  by [CONTACT_741807] /syringes at Visit 6,  and documented.  
 Participants should be instructed to return the unused ODT and syringes at Visit [ADDRESS_1014204] be 
maintained and reconciled with study intervention and compliance records. Intervention start and 
stop dates, including dates for intervention delays and/or dose reductions will also be recorded.  
Approved on 02 Nov 2022 GMT
CCI
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 32 6.5. Dose Modi fication  
No dose modification will be allowed during the study.  
6.6. Continued Access to Study Intervention after the End of the Study  
Study intervention will not be made available to participants after conclusion of the study .  
6.7. Treatment of Overdose  
In the event of an overdose, it is recommended that the participant  be monitored for any signs or 
symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately . 
The treating physician should:  
● Contact [CONTACT_741808].  
● Evaluate the participant to determine, in consultation with the medical monitor, whether 
study intervention should be interrupted.  
Refer to Nurtec ODT® USPI (20 21) for details related to overdose of rimegepant ODT.  
6.8. Concomitant Therapy  
See Sect ion 10.[ADDRESS_1014205] of allowed/not allowed medications will be communicated to 
investigators and will not constitut e a protocol amendment. The concomitant use of acute 
medications to treat migraine is allowed, with some limitations. Treatments used for the 
prevention of migraine, including nutraceuticals , pharmacological  and nonpharmacological 
interventions, are not al lowed at any time during Study Period II or III . Participant s should have 
washed out all migraine preventive treatments at least 5 days prior to Visit 2 . 
Botulinum toxin A or B in the head or neck area for therapeutic use is not allowed within 3 
months prior to Visit 2. Nerve blocks or use of therapeutic devices (such as transcranial magnetic 
stimulation) in the head or neck area or for  migraine prevention are not allowed within 30 days 
before Visit 2.  
Participant s will capture whether they took any acut e headache medication as part of their daily 
ePRO diary  entry during Study Periods II  and III. Acute headache medication name, dose, and 
date will  be recorded by [CONTACT_3445] s during Study Periods II  and III on a headache medication 
log, whic h will be retur ned to site staff at Visit 6 (the final study vi sit) or early discontinuation 
visit.  
For acetaminophen  (or paracetamol) , the maximal allowed dose will be 3  g/day from all 
acetaminophen -containing medicinal products . 
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or receives 
during the study must be recorded along with:  
● Reason for use  
● Dates  of administration including start and end dates  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 33 ● Dosage information including dose and frequency for concomitant therapy of 
special interest  
The medical monitor should be contact[CONTACT_63193].  
Treatm ents used for the prevention of migraine, including nutraceuticals, pharmacological and 
nonpharmacological interventions , are not allowed  at any time during Study Periods II and III . 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 34 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  
Discontinuation of specific sites or of the study as a whole are handled as part of Section 10.1.8 . 
7.1. Discontinuation of Study Intervention  
In rare instances, it may be necessary for a participant to permanently discontinue study 
intervention. If study intervention is permanently discontinued , the participant should  remain in 
the study to be evaluated for safety  and efficacy  assessments , unless criteria in Section 7.2 apply .  
A participant should be permanently discontinued from study intervention if :  
 the participant becomes pregnant during the study  (see Section 8.3.2 ) 
 the participant requests to discontinue  study intervention  
 clinical judgment  of the investigator  
7.1.1.  Liver Chemistry Stoppi[INVESTIGATOR_741782] -
normal baseline liver tests  
In study participants with normal or near normal baseline liver tests (ALT, AST, ALP <1.5x 
ULN), the study drug should be interrupted and close hepatic monitoring initiate (see Section 
10.5.2 ) if one or more of these conditions occur:  
Elevation  Exception  
ALT or AST >8x ULN   
ALT or AST >5x ULN for more than [ADDRESS_1014206] >3x ULN and either TBL >2x ULN or INR >1.5  For participants with Gilbert’s syndrome: If 
baseline direct bilirubin is >0.5 mg/dL, then 
the doubling of direct bilirubin should be 
used for drug interruption decisions rather 
than TBL  >2x ULN.  
ALT or AST >3x ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)   
ALP >3x ULN when the source of increased ALP is the liver   
ALP >2.5x ULN and TBL >2x ULN  For participants w ith Gilbert’s syndrome: If 
baseline direct bilirubin is >0.5 mg/dL, then 
the doubling of direct bilirubin should be 
used for drug interruption decisions rather 
than TBL  >2x ULN.  
ALP >2.5x ULN with the appearance of fatigue, nausea, vomiting, 
right upper q uadrant pain or tenderness, fever, rash, and/or 
eosinophilia (>5%)   
Source: FDA Guidance for Industry: Drug -Induced Liver Injury: Premarketing Clinical Evaluation, July 2009  and 
other consensus guidelines, with minor modifications . 
 
  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 35 Interrupting study drug based on elevated liver tests in participants with abnormal 
baseline liver tests  
In study participants with abnormal baseline liver tests (ALT, AST, ALP ≥1.5x ULN), the study 
drug should be interrupted  if one or more of these conditions occur:  
Elevati on Exception  
ALT or AST >4x baseline   
ALT or AST >3x baseline for more than [ADDRESS_1014207] >2x baseline and either TBL >2x ULN or INR  >1.5  For participants with Gilbert’s syndrome:  
If baseline direct bilirubin is >0.5 mg/dL, 
then the doubling of direct bilirubin should 
be used for drug interruption decisions 
rather than TBL  >2x ULN.  
ALT or AST >2x baseline with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)   
ALP >2.5x baseline when the source of increased ALP is the liver   
ALP >2x baseline and TBL >2x ULN  For participants with Gilbert’s syndrome:  
If baseline direct bilirubin is >0.5 mg/dL, 
then the doubling of direct bilirubin should 
be used for drug interruption deci sions 
rather than TBL  >2x ULN.  
ALP >2x baseline with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)   
Source: FDA Guidance for Industry: Drug -Induced Liver Injury: Premarketing Clinical Evaluation, July [ADDRESS_1014208] results return to baseline , and if a self -limited non-drug etiology 
is identified. Otherwise, the study drug should be discontinued.  
For suggested actions and follow -up hepatic assessments, see Section 10.5. 
7.1.2.  QTc Stoppi[INVESTIGATOR_42224] a clinically significant finding is identified (including, but not limited to , changes from 
baseline in QT interval corrected using Fridericia’s formula [QTcF ]) after enrollment, the 
investigator or qualified designee will determine if the participant  can continue in the study  and 
if any change in participant  management is needed . This review of the ECG printed at the time of 
collection  must be documented . Any new clinically relevant finding should be reported as an AE.  
7.2. Participant Discontinuation/ Withdrawal from the Study  
A participant  may withdraw from the study :  
● at any time at his/her own request  
● at the request of his/her designee (for example, par ents or legal guardian)  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 36 ● at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons  
● if enrollment in any other clinical study involving an investigational product or 
enrollment in any other type of medical resear ch judged not to be scientifically or 
medically compatible with this study  
● if the participant , for any reason, requires treatment with another therapeutic agent 
that has been demonstrated to be effective for treatment of the study indication, 
discontinua tion from the study occurs prior to introduction of the new agent . 
Discontinuation is expected to be uncommon.  
At the time of discontinuing from the study, if possible, an early discontinuation visit should be 
conducted, as shown in the SoA. See SoA for da ta to be collected at the time of study 
discontinuation and follow -up and for any further evaluations that need to be completed.  The 
participant will be permanently discontinued from both the study intervention and the study at 
that time.  
If the participant  withdraws consent  for disclos ure of future information, the s ponsor may retain 
and continue to use any data collected before such a withdrawal of consent . If a participant  
withdraws from the study, he/she may request destruction of any samples taken and not tested , 
and the investigator must document this in the site study records .  
7.3. Lost to Follow  up 
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_690646]. Site personnel or designee are 
expected to make diligent attempts to contact [CONTACT_10971] a scheduled visit 
or were otherwise unable to be followed up by [CONTACT_779].   
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 37 8. Study Assessments and Procedures  
 Study procedures and t heir timing are summarized in the SoA.   
 Immediate  safety concerns  should be discussed with the s ponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study intervention . 
 Adherence to the study design  requirements, including those specified in the SoA, is 
essential and required for study conduct.  
 All screening evaluations must be completed and reviewed to confirm that  potential 
participant s meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participant s screened and to confirm eligibility or record reasons for 
screening failure, as applicable.   
8.1. Efficacy Assessments  
8.1.1.  Primary Efficacy Assessment  
[IP_ADDRESS].  ePRO Diary  
Starting at Visit 2, p articipants will be asked to use an ePRO device to record headache 
information, including reporting headaches, intensity of headache, headache features, and 
whether any acute headache medication was taken. The system also will be used to collect 
information about migraine -associate d symptoms (for example, photophobia, phonophobia, 
nausea, and/or vomiting).  
8.1.2.  Secondary Efficacy Assessments  
[IP_ADDRESS].  Migraine -Specific Quality of Life Questionnaire Version 2.1 
The Migraine -Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1) is a self -
administered health status instrument that was developed to address the physical and emotional 
impact on functioning that is of specific concern to individuals suffering from migraine 
headaches .  
The instrument consists of 14 items that address 3 domains: (1)  Role Function -Restrictive; (2) 
Role Function -Preventive; and (3) Emotional Function ( Jhingran et al. 1998b) . The restrictive 
domain specifically measures disability as related to the impact on performance of normal 
activities, with the preventive domain a ddressing complete functional impairment and the 
emotional domain assessing the feelings related to disabling monthly migraine headache days. 
Responses are given using a 6-point Likert -type scale, ranging from “none of the time” to “all of 
the time.” Raw s cores for each domain are computed as a sum of item responses, with the 
collective sum providing a total raw score that is then converted to a 0  to 100 scale, with higher 
scores indicating a better health status, and a positive change in scores reflecting functional 
improvement (Jhingran et al. 1998a; Martin et al. 2000).  The instrument was designed with a 
4-week recall period and is considered reliable, valid, and sensitive to change in functional 
impairment due to migraine ( Jhingran et al. 1998b; Bagley e t al. 2012 ). 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 38 [IP_ADDRESS].  Migraine Disability Assessment  
The Migraine Disability Assessment (MIDAS) is a patient -rated scale which was designed to 
quantify headache -related disability over a [ADDRESS_1014209] 3  months of 
assessment, ranging from 0 to 90, with the total score being the summation of the 5 numeri c 
responses. A higher value is indicative of more disability ( Stewart et al. 1999 a, 1999b , 2001 ).  
This instrument is considered highly reliable and valid, and is correlated with clinical judgment 
regarding the need for medical care (Stewart et al. 1999 a, 1999b , 2001). For clinical 
interpretability, 4 categorical grades were developed based on the total score: Grade I (0 to 5) is 
for little or no disability, Grade II (6 to 10) is for mild disability, Grade III (11  to 20) is for 
moderate disability, and Grade IV (21+) is for severe disability. The severe disability category 
has subsequently been subdivided into Grade IV -A (severe [21 to 40]) and Grade IV -B (very 
severe [41 to 270]) because a high proportion of patients with chronic migraine are in Grade I V 
(Blumenfeld et al. 2011).  
8.1.3.  Tertiary Efficacy Assessment  
[IP_ADDRESS].  The Patient Global Impression of Severity  
The Patient Global Impression of Severity (PGI -S) scale (Guy 1976) is a patient -rated instrument 
that measures illness severity. For this study, the particip ant will be instructed as follows: 
“Considering migraine as a chronic condition, how would you rate your level of illness?” The 
PGI-S includes a range of possible responses, from 1 (“normal, not at all ill”) to 7 (“extremely 
ill”). 
8.2. Safety Assessments  
Plann ed time points for all safety assessments are provided in the SoA.  
8.2.1.  Physical Examinations  
 A complete physical examination will include, at a minimum, assessments of the 
cardiovascular, respi[INVESTIGATOR_696], gastrointestinal , and neurological  systems. Height and weig ht 
will also be measured and recorded.  
 Neurological examinations will be conducted to assess for any signs of preexisting or 
treatment -emergent neurological abnormalities.   
Investigators should pay special attention to clinical signs related to previous se rious illnesses.  
8.2.2.  Vital Signs  
Vital signs will include body temperature, blood pressure, and pulse. Blood pressure and pulse 
will be measured in triplicate in the sitting position after the participant  has rested for at least 5 
minutes, and before collectio n of blood samples and dosing  (if dosing is on the same day) , 
according to the SoA (Section  1.3), and following the study -specific recommendations included 
in the Reference Manual  for the study.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 39 8.2.3.  Electrocardiograms  
Single  12-lead ECG will be obtained as outlined in the SoA (see Section  1.3) and Reference 
Manual  using an ECG machine that automatically calculates  the heart rate and measures PR, 
QRS, QT, and QTcF intervals. In the event the ECG machine does not automatically calculate 
the QTcF interval, the QTcF interval may be manually calculated.  ECGs  should be collected 
prior to blood draws and dosing. Participant s must be supi[INVESTIGATOR_17044] [ADDRESS_1014210] be 
retained with source documents unless a Source Documen t Agreement or comparable document 
cites an electronic locat ion that accommodates the expected retention duration. Clinically 
significant abnormal laboratory findings are those which are not associated with the underlying 
disease, unless judged by [CONTACT_19448] ’s 
condition.  
All laboratory tests with values considered clinically significantly abnormal during the double -
blind treatment period  should be repeated until the values return to normal or baseline or are no 
longer considered clinically significant by [CONTACT_10982].  
 If such values do not return to normal/baseline within a period of time judged reasonable 
by [CONTACT_093], the etiology should be identified and the sponsor notified.  
 All protocol -required laboratory assessments, as def ined in Appendix [ADDRESS_1014211] collection requirements , and laboratory 
manual . 
If laboratory values from non -protocol specified l aboratory assessments performed at an 
investigator -designated local laboratory require a change in participant management or are 
considered clinically significant by [CONTACT_093] ( for example , SAE or AE or dose 
modification), then  report the informatio n as an AE .  
8.2.5.  Pregnancy Testing  
WOCBP must undergo pregnancy testing according to the SoA.  
8.2.6.  Suicidal Ideation and Behavior Risk Monitoring  
Participant s with migraine  may occasionally develop SIB. 
Participants who experience signs of SIB should undergo a risk assessment. All factors 
contributing to SIB should be evaluated and consideration should be given to discontinuation of 
the study intervention .  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 40 When informed consent or assent has been given , participants /caregivers  should be alerted about 
the emerge nce of unusual changes in behavior, as well as the emergence of SIB and to report 
such symptoms immediately to the study investigator.  
8.3. Adverse Events , Serious Adverse Events , and Product Complaints  
The definitions of the following events can be found in Appendix 3 : 
 AEs 
 SAEs  
These events will be reported by [CONTACT_2299] (or, if necessary , by a caregiver, surrogate, or the 
participant ’s legally authorized representative).  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet these definitions and remain responsible for following up events that 
are serious, considered related to the study intervention or study  procedures, or that caused the 
participant to discontinue the study intervention  or the study (see Section 7). 
Care will be taken not to introduce bias when detecting events. Open -ended and non -leading 
verbal questioning of the participant is the preferred method to inquire about event occurrences.  
After the initial report, the investigator is required to proactively follow each participant at 
subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event is 
otherwise explained, or the participant is lost to follow -up (as defined in Section 7.3).  
For PCs, the unblinded site personnel are responsible for ensuring that follow -up includes any 
supplemental investig ations as indicated to elucidate the nature and/or causality.  
A PC is any written, electronic, or oral communication that alleges deficiencies related to the 
identity, quality, durability, reliability, safety, effectiveness, or performance of a trial 
intervention. When the ability to use the study intervention safely is impacted, the following are 
also PCs: 
 Deficiencies in labeling information, and  
 Use errors for device or drug -device combination products due to ergonomic design 
elements of the product.  
Sponsor collects PCs on study interventions and drug delivery systems used in clinical studies in 
order to ensure the safety of study participants, monitor quality, and to facilitate process and 
product improvements.  
Participants will be instructed to cont act the investigator as soon as possible if he or she has a 
complaint or problem with the study interventions so that the situation can be assessed. Note: 
The designated unblinded site personnel are responsible for handling all aspects of PCs. 
Note: AEs/SA Es that are associated with a PC will also follow the processes outlined in 
Section  8.3.1  of the protocol.  
For the time periods for detecting and repo rting PCs, see Section 8.3.1 . 
 Follow -up applies to all participants, including those who discontinue study intervention.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 41  The investigator is responsi ble for ensuring that follow -up includes any supplemental 
investigations as indicated to elucidate the nature and/or causality of the PC. 
 New or updated information will be recorded on the originally completed PC form with 
all changes signed and dated by t he investigator and submitted to the sponsor.  
Note: An event may meet the definition of both a PC and an AE/SAE. In such cases, it 
should be reported as both a PC and as an AE/SAE.  
8.3.1.  Timing and Mechanism for Collecting Events  
This table describes the timing, deadlines , and mechanism for collecting events.  
Event  Collection 
Start  Collection 
Stop  Timing for Reporting 
to Sponsor or 
Designee  Mechanism for 
Reporting  Back -Up 
Method of 
Reporting  
Adverse Event  
AE Signing of 
the ICF  Participation 
in study has 
ended  As soon as possible 
upon site awareness  AE CRF  N/A 
Serious Adverse Event  
SAE and SAE 
updates – prior 
to start of study 
intervention and 
deemed 
reasonably 
possibly related 
with study 
procedures  Signing of 
the ICF  Start of 
intervention  Within 24 hours of 
awareness  SAE paper form  SAE paper 
form  
SAE  and SAE 
updates  – after 
start of study 
intervention  Start of 
intervention  Participation 
in study has 
ended  Within 24 hours of 
awareness  SAE paper form  SAE paper 
form  
SAEa – after 
participant’s 
study 
participation has 
ended and the 
investigator 
becomes aware  After 
participant’s 
study 
participation 
has ended  N/A Promptly  SAE paper form  N/A 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 [ADDRESS_1014212] 
subcutaneous  
injection of 
study 
intervention  Within 24 hours (see 
Section 8.3.2 ) Pregnancy paper 
form  N/A 
Product Complaints  
PC associated 
with an SAE  or 
might have led 
to an SAE  Start of study 
intervention  End of study 
intervention  Within 24 hours of 
awareness  PC form  N/A 
PC not 
associated with 
an SAE  Start of study 
intervention  End of study 
intervention  Within 1 business day 
of awareness  PC form  N/A 
Updated PC 
information  — — As soon as possible 
upon site awareness  Originally 
completed PC form 
with all changes 
signed  and dated by 
[CONTACT_093]  N/A 
PC (if 
investigator 
becomes aware)  Participation 
in study has 
ended  N/A Promptly  PC form   
Abbreviations: AE = adverse event;  CRF = case report form; ICF = informed consent form; N/A = not applicable; 
PC = product complaint;  SAE = severe adverse event; WOCBP = woman of childbearing potential.  
a SAE s after study participation  should not be reported unless the investigator deems them to be possibly related to 
study treatment  or study participation . 
8.3.2.  Pregnancy  
Collectio n of pregnancy information  
Male participants with partners who become pregnant  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 43 ● The investigator will attempt to collect pregnancy information on any male 
participant’s female partner who becomes pregnant while the male participant is 
in this study. This applies only to male participants who receive study 
intervention . 
● After obtaini ng the necessary signed informed consent from the pregnant female 
partner directly, the investigator will record pregnancy information on the 
appropriate form and submit it to the sponsor within 24 hours of learning of the 
partner’s pregnancy. The female partner will also be followed to determine the 
outcome of the pregnancy. Information on the status of the mother and child will 
be forwarded to the sponsor. Generally, the follow -up will be no longer than 6 to 
8 weeks following the estimated del ivery date. Any termination of the pregnancy 
will be reported regardless of gestational age, fetal status (presence or absence of 
anomalies) or indication for the procedure.  
Female participants who become pregnant  
● The investigator will collect pregnancy  information on any female participant 
who becomes pregnant while participating in this study. The initial information 
will be recorded on the appropriate form and submitted to the sponsor within 24 
hours  of learning of a participant ’s pregnancy.  
● The pa rticipant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on the participant and the neonate 
and the information will be forwarded to the sponsor. Generally, follow -up will 
not be required for  longer than 6 to 8 weeks beyond the estimated delivery date. 
Any termination of pregnancy will be reported, regardless of gestational age, fetal 
status (presence or absence of anomalies) or indication for the procedure.  
● While pregnancy itself is not con sidered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE.  
● A spontaneous abortion (occurring at <20 weeks gestational age) or still birth 
(occurring at ≥20 weeks ge stational age) is always considered to be an SAE and 
will be reported as such.  
● Any post -study pregnancy -related SAE considered reasonably related to the study 
intervention by [CONTACT_741809] 8.3.1 . While the investigator is not obligated to actively seek this 
information in former study participants, he or she may learn of an SAE throu gh 
spontaneous reporting.  
● Any female participant who becomes pregnant while participating in the study 
will discontinue study intervention. If the participant is discontinued from the 
study, follow the standard discontinuation process. The follow  up on t he 
pregnancy outcome should continue independent of intervention or study 
discontinuation .  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 44 8.4. Pharmacokinetics  
PK parameters are not evaluated in this study . 
8.5. Pharmacodynamics  
PD parameters a re not evaluated in this study . 
8.6. Genetics  
Genetics is not evaluated in this study.  
8.7. Biomarkers  
Biomarkers are not evaluated in this study.  
8.8. Immunogenicity Assessments  
Immunogen icity assessments are not evaluated in this study.  
8.9. Health Economic s 
Medical resource utilization and health economics parameters are not evaluated in this study . 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 [ADDRESS_1014213] important endpoints , including primary and key 
secondary endpoin ts. 
9.1. Statistical Hypotheses  
The primary objective is to demonstrate that galcanezumab  is superior to rimegepant  in reducing 
migraine headaches as measured by [CONTACT_741810] a 3 -month period (in 
this case, the 3 -month double -blind perio d). If one lets πG and πR = the true 3-month average 
monthly 50% response rates for galcanezumab and rimegepant respectively , the null and 
alternative hypothes es are as follows : 
H0: 𝜋𝐺 ≤ 𝜋𝑅 against Ha: 𝜋𝐺 > 𝜋𝑅 
The corresponding hypotheses for secondary objectives with response rate based estima nds (for 
example , average monthly 75% response rate) are identical as those for the primary ( with 
corresponding changes to the true response rate of interest) .  
For second ary objectives that are to demonstrate the  superiority of galcanezumab over 
rimegepant as measured by [CONTACT_741811] ( for example,  reduction from baseline in 
monthly migraine headache days) , the null and alternative hypothe ses would be of the form:  
H0: 𝜇𝐺 ≤ 𝜇𝑅 against Ha: 𝜇𝐺 > 𝜇𝑅 
Where μG and μR are the true mean reductions for galcanezumab and rimegepant , respectively.  
While all hypotheses given above are 1 -sided, these hypotheses will operationally be evaluated 
via 2 -sided tests.  
9.1.1.  Multiplicity Adjustment  
The statistical comparisons for the primary efficacy endpoint and the key secondary endpoints 
will be carried out in the hierarchical order as indicated in Section 3. This means that statistically 
significant results for the comparison in the higher rank (primary, then ranked secondary 
variables) are required to initiate the testing of the next comparison in the lower rank. Since a 
step-down procedure is used, each comparison will be tested at a significance level of 0.05 and 
an overall alpha level of 0.05 will be preserved . 
The order of objectives /comparisons may change (with the exception of the primary o bjective ). 
Should such a change take place, the  final hierarchical order  used/multiplicity adjustment 
approach employed to ensure overall 0.05 alpha -level control will be documented within an 
approved final SAP prior to study unblinding . 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 46 9.2. Analyses  Sets 
Participant Analysis Set  Description  
Intention  to Treat (ITT) set  All randomized participants  and receive at least 1 dose of study 
intervention . Participants will be included in the analyses 
according to th eir randomized treatment . 
Safety analysis set  All participants who are exposed to study intervention . 
Participants will be analyzed according to the treatment  they 
actually received.  
9.3. Statistical Analyses  
9.3.1.  General Considerations  
Statistical analysis of this study will be the responsibility of Lilly or its designee. Details of 
statistical analysis methods will be described in the SAP with the final SAP approved prior to 
study unblinding being the official version for this stud y.  
Unless otherwise specified, analyses will be conducted on the ITT population for efficacy 
analyses and on the safety population for safety analyses (see Section 9.2). When change from 
baseline is assessed, the participant  will be included in the analysis only if he/she has a baseline 
and a postbaseline measurement . 
Binary efficacy variables with repeated measures will be analyzed using a GLIMMIX as pseudo -
likelihood -based mixed effects repeated measures analysis. The GLIMMIX model will include 
the fixed, categorical effects of treatment, month, and treatment -by-month  interaction, as well as 
the continuous, fixed covariate of baseline monthly migraine headache days  value.  
For binary efficacy variables without repeated measures, comparisons between treatment groups 
will be performed using logistic regressions with LOCF imputation being used. This model will 
include  the main effects of treatment  and a continuous effect for baseline monthly migraine 
headache days .  
Continuous efficacy variables with repeated measures will be analyzed using MMRM methods.  
The MMRM will inclu de the fixed categorical effects of treatment, month, and treatment -by-
month interaction, as well as the continuous fixed covariates of baseline and baseline -by-month 
interaction. Wherever possible an unstructured covariance matrix will be used to model th e 
correlation structure among repeated measures. A list of other covariance structures to be used in 
case of nonconvergence will be given within the SAP.  
For continuous efficacy variables without repeated measures, an ANCOVA model with LOCF 
imputation will  be used, which contains the main effects of treatment, and the continuous fixed 
covariate of baseline. T ype III sum -of-squares for the LSMeans will be used for the statistical 
comparisons.  
For continuous safety variables with repeated measures, MMRM metho ds will be used, as well 
as an ANCOVA model with LOCF imputation if deemed appropriate. When an ANCOVA 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 [ADDRESS_1014214] of treatment, as well as 
the continuous fixed covariate of baseline. Type  III sum -of-squares for the LSMeans will be used 
for the statistical comparisons.  
For categorical safety variables (such as AEs and other categorical changes of interest), 
comparisons between treatment groups will be performed using Fisher’s exact test.  
Treatment effects will be evaluated based on a 2 -sided significance level of 0.05 for all the 
efficacy and safety analyses unless otherwise stated. The 95% confidence intervals for the 
difference in LSMeans between treatment groups will be presented. Type I e rror due to multiple 
comparisons for the primary and key secondary objectives will be controlled using sequential 
gating procedure (see Section 9.1.1 ). There will be no adjustments for multiplicity for analyses 
of other data (other secondary objectives or tertiary objectives) .  
9.3.2.  Primary Endpoint (s)/Estimand(s)  Analysis  
The primary endpoint is based on the percentage of participant s showing a  50% response  on each 
month , defined as showing  50% or fewer migraine headache days within th e month than was 
seen during the baseline period.  The primary estimand of interest is the overall  mean monthly 
50% response rate across the 3-month double -blind period attributable to the randomized 
treatment  based on all available data  as estimated from the GLIMMIX model . Here all available  
monthly migraine headache data will contribute to analysis as long as baseline monthly migraine 
headache  day values are available. Any migraine headache day data collected after study 
intervention discontinuation but within the double -blind period will still  be used within the 
analysis . 
The primary analysis method will be the  GLIMMIX  given in Section 9.3.1  above for binary data.  
If the sample size is increased as a result of the interim analysis, the CHW procedure (Cui et al. 
1999) will be applied to the primary endpoint to control the type I error at a one -sided α = 0.025 
significance level. The CHW method ensures strong control of type I error when the sample size 
is increased in a data dependent manner.  
If the sample size is increased as a result  of the interim analysis, an unadjusted point estimate for  
the primary efficacy analysis will be calculated and reported. A median unbiased point estimate  
and a stage -wise adjusted confidence interval for the primary efficacy analysis will be calculated  
and reported based on the approach described by [CONTACT_741812]. (2009)  to assess sensitivity of 
the point estimate . 
9.3.3.  Secondary Endpoint s/Estimand s Analysis  
For all secondary endpoints, a similar estimand to the one used for the primary analysis will be 
employ ed. That is, the estimand of interest will be based on mean monthly estimates 
across /within  the double -blind period and will be based on all available data during that period 
(even if collected after study intervention discontinuation) . Additionally , basel ine values must 
also be available.  
The corresponding analyses for each of these endpoints will be as stated within Section 9.3.1  
based on the  type of endpoint measured ( that is , binary or continuous).   
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 [ADDRESS_1014215] statistic will be calculated for the  key secondary 
endpoints  before apply ing multiple testing procedure . 
9.3.4.  Safety Analyse s 
The safety and tolerability of treatment will be assessed by [CONTACT_176181]:  
 TEAEs  
 SAEs  
 AEs leading to discontinuation  
 AEs related to injection sites  
 vital signs  
 laboratory measurements  
Unless specified otherwise, the categorical safety analyses will include both scheduled and 
unscheduled visits. Comparisons between treatment groups for all categorical safety measures 
will be made using Fisher’s exact test within the safety population .  
[IP_ADDRESS].  Treatment -Emergent Adverse Events  
TEAEs  are defined as the reported AEs that first occurred or worsened during the postbaseline 
period  compared with the baseline period . For each TEAE, the reported severity level of the 
event (mild, moderate, or severe) will be determined by [CONTACT_476201][INVESTIGATOR_1649].  The MedDRA LLT 
will be used in the treatment -emergent computation. For each LLT, the maximum severity at 
baseline will be used as the baseline severity. If the maximum severity during postbaseline is 
greater than th e maximum baseline severity, the event is considered to be treatment -emergent for 
the specific postbaseline period. Safety analyses for each study period will use all visits up 
through the last scheduled visit in the prior study period as baseline. For eac h participant  and 
TEAE, the maximum severity for the MedDRA level being displayed (preferred term, High -
Level Term, or System Organ Class [ SOC ]) is the maximum postbaseline severity observed from 
all associated LLTs mappi[INVESTIGATOR_355690].  
For events  that are sex -specific, the denominator and computation of the percentage will include 
only participant s from the specific sex.  
[IP_ADDRESS].  Vital Signs  
Vital signs collected during the study include systolic and diastolic blood pressure, pulse, and 
temperature. For vi tal signs procedures see Section 8.2.2 .  
The number and percentage of participant s meeting criteria for treatment -emergent abnormalities 
in vital sig ns at any time during study will be summarized. Treatment group comparisons will be 
performed using Fisher’s exact test.  
[IP_ADDRESS].  Laboratory Tests  
The incidence rates of participant s with treatment -emergent abnormal, high, or low laboratory 
values at any time postb aseline will be assessed using Fisher’s exact test for each laboratory test.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 49 9.3.5.  Other Analyses  
Details of analyses of other endpoints not falling under either efficacy or safety will be provided 
within the SAP.  
9.4. Interim Analys is 
One interim analysis is planned for this study. The interim analysis will occur during Study 
Period III (double -blind treatment); this may result in increasing the sample size or continuing 
with the planned sample size . Details will be documented in the SAC SAP and ERB supplement.  
To minimize the potential bias that results from performing an interim analysis, the interim 
analysis for this study will be conducted by a SAC  external to the study team . 
Only the SAC  is authorized to evaluate unblinded interim a nalyses results  to make an inform ed 
decision. Study sites will receive information about interim results ONLY if they need to know 
for the safety of their patients.  
Unblinding details will be  specified in the unblinding plan section of the SAP or a separat e 
unblinding plan document.  
9.5. Sample Size Determination  
The study will screen an estimated 1150 potential study participants to ensure a minimum of  
approximately 575 randomized participan ts. Based on the assumption of treatment difference  of 
12%, the minimum sample size of approximately 575 provides more than 85% power at a two -
sided significance level of 5% and a dropout rate of no more than 10% , with the opportunity to 
increase the final sample size  at the interim analysis if indicated to main tain a well -powered 
study.  To preserve  blinding, details of the sample size and power calculations are omitted from 
this protocol and are  provided to the ERB in a separate document.  If the interim is not 
performed , then the trial will enro ll to a sample si ze as specified in the ERB document.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 50 10. Supporting Documentation and Operational Considerations  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1.  Regulatory and Ethical Considerations  
● This study will be conducted in accordance with the protocol and with the 
following:  
○ Consensus ethical principles derived from international guidelines including 
the Declaration of Helsinki and Council for International Organizations of 
Medical Sciences (CIOMS) International Ethical Guidelines  
○ Applicable ICH GCP Guidelines  
○ Applicable laws and regulations  
● The protocol, protocol amendments, ICF, IB, and other relevant documents ( for 
example , advertisements) must be submitted to an IRB/IEC by [CONTACT_741813] B/IEC  before the study is initiated.  
● Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants.  
● Protocols and any substantial amendments to the protocol will require health 
authority approval prior to initiation except for changes necessary to eliminate an 
immediate hazard to study participants . 
● The investigator will be responsible for the following:  
○ Provi ding written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, and 
procedures established by [CONTACT_1201]/IEC . 
○ Notifying the IRB/IEC of SAEs  or other significant safety findings as r equired 
by [CONTACT_1744]/IEC procedures . 
○ Providing oversight of study conduct for participants under their responsibility 
and adherence to requirements of 21 C ode of Federal Regulations (C FR), ICH 
guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if 
applicable), and all other applicable local regulations . 
● Investigator sites are compensated for participation in the study  as detailed in the 
CTA . 
10.1.2.  Informed Consent Process  
● The investigator or his/her representative will explain the nature of the study , 
including the risks and benefits,  to the participant , and answer all  questions 
regarding the study.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 51 ● Participants must be informed that their participation is voluntary. Participants  
will be required to sign a statement of informed consent t hat meets the 
requirements of 21 CFR 50, local regulations, ICH guidelines, privacy and data 
protection requirements, where applicable, and the I RB/IEC or study center.  
● The medical record must include a statement that written informed consent was 
obtaine d before the participant was enter ed in the study and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.  
● Participants must be reconsented to the most current version of the ICF(s) durin g 
their participation in the study.  
● A copy of the ICF(s) must be provided to the participant and is kept on file .  
Participants who are rescreened are required to sign a new ICF.  
10.1.3.  Data Protection  
● Participants will be assigned a unique identifier by [CONTACT_456]. Any participant 
records , datasets  or tissue samples  that are transferred to the sponsor will contain 
the identifier only; participant names or any information which would make the 
participant identi fiable will not be transferred.  
● The participant  must be informed that his/her personal study -related data will be 
used by [CONTACT_10999]. The level of 
disclosure must also b e explained to the participant  who will be required to give 
consent for his/her data to be used as described in the informed consent .  
● The participant must be informed that his/her medical records may be examined 
by [CONTACT_103083], by [CONTACT_6667]/IEC members, an d by [CONTACT_9326].  
● The sponsor has processes in place to ensure data protection, information security 
and data integrity. These processes include appropriate contingency plan(s) for 
appropriate and timely response in the event of a data security breach.  
10.1.4.  Committees Structure  
Potential cardiovascular events will be adjudicated by [CONTACT_471934]. The role of the CEC is to 
adjudicate defined clinical events in a blinded, consistent, and  unbiased manner throughout the 
course of a st udy. The purpose of the CEC for adjudication of cardiovascular events is to ensure 
that all reported events are evaluated uniformly by a single group.   
Death , resuscitated cardiac arrest , and p otential treatment -emergent cardiovascular events from 
the CRF will be identified using a search strategy based on the 9  MedDRA SMQs listed below. 
Narrow terms from the se SMQ s will be adjudicated if they are reported as a  SAE . Potential  non-
serious cardiovascular events may be selected for adjudicat ion following blinded medical review . 
Details of membership, operations, recommendations from the Committe e, and the 
communication plan will be documented in the charter.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 52 Narrow terms in the following SMQs will be a djudicated:  
 Cardiac arrhythmias (includes sub SMQs; SM Q 20000049)  
 Cardiac failure (SMQ 20000004)  
 Cardiomyopathy (SMQ 20000150)  
 Central nervous system vascular disorders (includes sub SMQs; SMQ 20000060)  
 Embolic and thrombotic events (includes sub SMQs; SMQ 20000081)  
 Hypertension (SMQ 20000147)  
 Ischemic  heart disease (includes sub SMQs; SMQ 20000043)  
 Pulmonary hypertension (SMQ 20000130)  
 Torsade de pointes/QT prolongation (SMQ 20000001)  
Case unblinding may be performed for above reviews , only if necessary  
10.1.5.  Dissemination of Clinical Study Data  
A clinical study report will be provided for this study and a summary of study information 
provided on publicly available websites.  
10.1.6.  Data Quality Assurance  
● All participant data relating to the study will be recorded on electronic CRF s 
unless transmitted to the sponsor or designee electronically ( for example , 
laboratory data). The investigator is responsible for verifying that data entries are 
accurate and correct by [CONTACT_11003].  
● The investigator must maintain accurate documentation (source data) that 
supports the inf ormation entered in  the CRF.  
● The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory agency inspections and provide direct a ccess to source data 
documents.  
● QTLs will be pre -defined to identify systematic issues tha t can impact participant 
safety and/or reliability of study results. These pre -defined parameters will be 
monitored during the study and important excursions  from the QTLs and remedial 
actions taken will be summarized in the clinical study report . 
● Monito ring details describing strategy ( for example , risk -based initiatives in 
operations and quality such as risk management and mitigation strategies and 
analytical risk -based monitori ng), methods, responsibilities and requirements, 
including handling of nonco mpliance issues and monitoring techniques are 
provided in the monitoring plan. 
● The sponsor or designee is responsible for the data management of this study 
includin g quality checking of the data.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 53 ● The sponsor assumes accountability for actions delegated  to other individuals ( for 
example , contract research organizations ). 
● Study monitors will perform ongoing source data verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and 
verifiable from source d ocuments; that the safety and rights of participants are 
being protected; and that the study is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP, and all 
applicable regu latory requirements.  
● Record s and documents, including signed ICFs, pertaining to the conduct of this 
study must be retained by [CONTACT_695475] a longer retention period. 
No records ma y be destroyed during the retention period without the written 
approval of the sponsor. No records may be transferred to another location or 
party without written notification to the sponsor . 
● In addition, sponsor  or its representatives will periodically check a sample of the 
participant data recorded against source documents at the study site. The study 
may be audited by [CONTACT_81284], and/or regulatory agencies at 
any time. Investigators will be given notice before an audit occurs.  
Data Capture System  
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor.   
An EDC system will be used in this study for the collection of CRF data. The investigator 
maintains a s eparate source for the data entered by [CONTACT_11002] -provided EDC system. The investigator is responsible for the identification of any data 
to be considered source and for the confirmation that data reported are accurate an d complete by 
[CONTACT_11003] . 
Additionally, eCOA data ( participant -focused outcome instrument ) will be directly recorded by 
[CONTACT_741814] ( handheld smart phone and/or tablet ). The eCOA data will 
serve as the source documentation and the investigator does not maintain a separate, written or 
electronic record of these data.  
Data collected via the sponsor -provided data capture system (s) will be  stored at third parties . The 
investigator will have continuous access to the data during the s tudy and until decommissioning 
of the data capture system s. Prior to decommissioning, the investigator will receive an archival 
copy of pertinent data for retention.  
Data managed by a central vendor, such as laboratory test data, will be stored electronica lly in 
the central vendor’s database system and reports  or electronic transfers  will be provided to the 
investigator for review and retention. Data will subsequently be transferred from the central 
vendor to the sponsor  data warehouse.  
Data from complaint forms submitted to sponsor  will be encoded and stored in the global PC 
management system.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 54 10.1.7.  Source Documents  
● Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
● Data entered in the eCRF that are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medical records or tr ansfer records, 
depending on the study. Also, current medical records must be available.  
● Definition of what constitutes source data can be found in Section 10.1.[ADDRESS_1014216] been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and suff icient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_11004]:  
For study termination:  
● Discontinuation of further study intervention developme nt 
For site termination:  
● Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor ’s procedures, or GCP guidelines  
● Inadequate recruitment (evaluated after a reasonable amount of ti me) of 
participants by [CONTACT_093]  
● Total number of participants included earlier than expected  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and a ny contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by [CONTACT_11005]. The investigator shall promptly inform the participant  and should assure 
appropriate participant  therapy and/or follow -up. 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 55 10.1.9.  Publication Policy  
In accordance with the sponsor’s publication policy , the results of this study will be submitted 
for publication by a peer -reviewed journal.  
10.1.10.  Investigator Information  
Physicians with a specialty in neurology , headache specialist,  or other physicians  with 
experience in headache clinical trial s and  diagnosing  and treating migraine participant s will 
participate as investigators in this clinical trial.  
  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 56 10.2. Appendix 2: Treatments Allowed and Treatments not Allowed as 
Concomitant Therapy  
 
A. Medications allowed for the ACUTE treatment of migraine headaches or other pain 
or injury:  
Acetaminophen (paracetamol), NSAIDs; Triptans; Ergotamine and derivatives ; aspi[INVESTIGATOR_248], caffeine , and 
acetaminophen combination; or combinations thereof. For acetaminophen, the maximal allowed dose will be 
3 g/day from all acetaminophen -containing medicinal products.  
 
The following medications are allowed with restrictions:  
1. Opi[INVESTIGATOR_229163] 4 days/month.  
2. Single dose of injectable steroids allowed only once during the study, in an emergency setting (SP II and III).  
 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 57 B. Medications, procedures or devices not allowed for any reason/indication  during SP II 
and III : 
Acetazolamide  
Acupuncture  
Anticonvulsants/Antiepi[INVESTIGATOR_741783]-blockers   
Botulinum toxin applied to head/neck area for therapeutic use  
Cannabis/Cannabinoidsb 
Chiropractic procedures, physiotherapy, TENS or other electric devices on head and neck  
Corticosteroids for oral usec 
CYP3A4: Moderate and strong inhibitors of CYP3A4  (includes Paxlovid)d  
CYP3A: Moderate and strong inducers of CYP3A  
Efflux transporters: Inhibitors of P -gp and BCRP  
Flunarizine  
Herbals with anti -inflammatory effect (feverfew, willo w bark, petasites/butterbur), herbals with sympathomimetic 
effect (ma huang, ephedra, bitter orange, synephrine) and herbals with catecholamine transmitter reuptake 
inhibition (St . John’s Wort)  
Migravent  
Monoamine oxidase inhibitors (MAOIs)  
Memantine  
Neuro tropin® 
Nerve block in head/neck area  
Serotonin 5HT2a/2c antagonists, for example: nefazodone  
Tizanidine  
Tricyclic antidepressants (TCAs)  
Triptans for prophylaxis of menstrual -related migraine  
Venlafaxine  and desvenlafaxine  
Verapamil  
C. Restricted medication during SP II and III : Use of the following medications for 
indications other than migraine prevention is allowed providing the dose is stable 
2 months prior to Visit 2 and is expected to remain stable during Visit 2 through 6 .  
ACE inhibitors  
Angiotensin receptor blockers (ARBs)  
Benzodiazepi[INVESTIGATOR_741784] -channel blockers (except verapamil and flunarizine)  
Clonidine  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 58 Gabapentin  
Guanfacine  
Mirtazapi[INVESTIGATOR_741785]/NRIs/SNRIs (other than venlafaxine)  
Stimulants (prescription strengt h), for example: methylphenidate, dextroamphetamine, mixed amphetamine salts  
Trazadone (for sleep only and must be taken in a stable fashion)  
Use of electric devices ( that is , TENS), physiotherapy, chiropractic procedures on low back and extremities  
 
D. Restricted medication during SP II -III: Use of the following medications for 
indications other than migraine prevention is allowed : 
Beta-blockers, ophthalmic  
Cyproheptadine  
Melatonin  
 
Abbreviations:  5HT = 5 -hydroxytryptamine; ACE = angiotensin -converting enzyme; NRI = norepi[INVESTIGATOR_120474]; NSAID = nonsteroidal anti -inflammatory drug; SNRI = serotonin -norepi[INVESTIGATOR_33518]; SP = Study Period; SSRI = selective serotonin reuptake inhibitor; TENS = transcutaneous electrical 
nerve stimu lation.  
a Gabapentin and pregabalin may be allowed if the criteria in Part C are met . 
b It may be allowed in the study if prescribed for a condition other than migraine or headache , as long as the use of 
Cannabis/Cannabinoids is not expected to affect the interpretation of study results or the safety of the participant.  
The usage should remain consistent for the duration of the study and criteria in exclusion 23ii  are met . 
c Topi[INVESTIGATOR_741786] h eadache . 
d Paxlovid is authorized by [CONTACT_741815] -to-moderate COVID -19 and contains 
ritonavir - a strong CYP3A4 inhibitor ; thus, is excluded in CGBD . 
  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 59 10.3. Appendix 3: Adverse Events and Serious Adverse Events: Definitions 
and Procedures for Recording, Evaluating, Follow -up, and 
Reporting  
10.3.1.  Definition of AE  
AE Definition  
 An AE is any untoward medical occurrence in a participant administered a 
pharmaceutical product and  which does not necessarily have a causal relationship with 
the study intervention. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with t he use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.  
Events Meeting the AE Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety ass essments (for example, ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator (that is, not related 
to progression of under lying disease).  
 Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency and/or intensity of the condition.  
 New condition detected or diagnosed after study intervention administration even 
though it may have  been present before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae.  
 Lack of efficacy or failure of expected pharmacological action per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, sym ptoms, and/or clinical sequelae resulting from lack of efficacy 
will be reported as AE or SAE if they fulfill the definition of an AE or SAE.  
Events NOT  Meeting the AE Definition  
 Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by [CONTACT_11009]’s condition.  
 The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.  
 Medical or surgical procedure (for example, endoscopy  and appendectomy): the 
condition that leads to the procedure is the AE.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 60  Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
 Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.   
10.3.2.  Definition of SAE  
An SAE  is defined as any untoward medical occurrence that, at any dose, meets 1 or 
more of the criteria listed:  
a. Results in death  
b. Is life -threatening  
The term life-threatening  in the definition of serious  refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_10909]  
 In general, hospi[INVESTIGATOR_541430] (usually involving at least an overnight stay) for observation and/or 
treatment that would not have been appropriate in the physicia n’s office or outpatient 
setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication 
prolongs hospi[INVESTIGATOR_9236], the event is serious. When 
in doubt as to whether hospi[INVESTIGATOR_51956], the AE should be 
considered serious.  
 Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.  
d. Results in persistent disability/incapacity  
 The term disability means a substantia l disruption of a person’s ability to conduct 
normal life functions.  
 This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental traum a (for example, sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
 Abnormal pregnancy outcomes ( for example , spontaneous abortion, fetal death, 
stillbirth, congenital anomalies,  and ectopic pregnancy) are considered SAEs.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 61 f. Other situations:  
 Medical or scientific judgment should be exercised by [CONTACT_741816] m edical 
events that may not be immediately life -threatening or result in death or hospi[INVESTIGATOR_51957]. These e vents should 
usually be considered serious.  
 Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059],  or development of drug dependency or 
drug abuse.  
10.3.3.  Recording and Follow -Up of AE and/or SAE  
For PCs, see Section 8.3.  
AE and SAE  Recording  
 When an AE/SAE  occurs, it is the responsibility of the investigator to review all 
documentation (for example, hospi[INVESTIGATOR_1088], laboratory reports, and 
diagnostics reports) related to the event.  
 The investigator will then record all relevant AE/ SAE information in the participant’s 
medical records, in accordance with the investigator’s normal clinical practice. 
AE/SAE information is reported on the appropr iate CRF  or paper form, respectively . 
 It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to sponsor or designee in lieu of completion of the CRF page or paper form, 
respectively, for AE/SAE . 
 There may be inst ances when copi[INVESTIGATOR_517482]. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_741787].  
 The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.   
Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to 1 of the following categories:   
 Mild: A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual activities of 
daily living.  
 Moderate: A type of AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activi ties of daily living, causing 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 62 discomfort but poses no significant or permanent risk of harm to the research 
participant.  
 Severe: A type of AE that interrupts usual activities of daily living, or significantly 
affects clinical status, or may require intensi ve therapeutic intervention. An AE that is 
assessed as severe should not be confused with an SAE. Severe is a category utilized 
for rating the intensity of an event; and both AEs and SAEs can be assessed as severe.  
An event is defined as “serious” when it meets at least 1 of the pre -defined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.  
Assessment of Causality  
 The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE. The investigator will use clinical judgment to 
determine the relationship . 
 A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship canno t be 
ruled out.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.  
 The investigator wil l also consult the IB and/or Product Information in his/her 
assessment.  
 For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
 There may be situations in which a n SAE has occurred and the investigator has 
minimal information to include in the initial report to sponsor or designee. However, it 
is very important that the investigator always make an assessment of causality for 
every event before the initial transmiss ion of the SAE data to sponsor or designee.  
 The investigator may change his/her opi[INVESTIGATOR_9242] -up 
information and send an SAE follow -up report with the updated causality assessment.  
 The causality assessment is one of the criteria u sed when determining regulatory 
reporting requirements.  
Follow -up of AEs and SAEs  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_741817]/or causality of the AE or SAE as fully as possible. 
This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other healthcare professionals.  
 If a participant d ies during participation in the study or during a recognized follow -up 
period, the investigator will provide sponsor or designee with a copy of any 
post-mortem findings including histopathology.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 63 10.3.4.  Reporting of SAEs  
SAE Reporting via Paper Form  
 Facsimile transmission of the SAE paper form is the preferred method to transmit this 
information to the sponsor or designee . 
 Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within th e designated reporting time frames.  
 Contacts for SAE reporting can be found in  site training documents .  
10.3.5.  Regulatory Reporting Requirements  
SAE Regulatory Reporting  
Prompt notification by [CONTACT_741818] a study intervention under clinical investigation are met.  
● The sponsor has a legal responsibility to notify both the local regulatory 
authority and other r egulatory agencies about the safety of a study intervention 
under clinical investigation. The sponsor will comply with country -specific 
regulatory requirements relating to safety reporting to the regulatory authority, 
IRBs/IEC s, and investigators.  
● An inv estigator who receives an investigator safety report describing an SAE or 
other specific safety information ( for example , summary or listing of SAEs) 
from the sponsor will review and then file it along with the IB or Product 
Information and will notify the  IRB/IEC, if appropriate according to local 
requirements.   
  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 64 10.4. Appendix 4: Clinical Laboratory Tests  
● The tests detailed in the table below will be performed by [CONTACT_741819] . 
● Local laboratory results are only required  in the event that the central laboratory 
results are not available in time for either study intervention administration and/or 
response evaluation. If a local sample is required, it is important that the sample 
for central analysis is obtained at the same  time, if feasible . Additionally, if the 
local laboratory results are used to make either a study intervention decision or 
response evaluation, the results must be recorded . 
● In circumstances where the sponsor allows  the use of local laboratory testing in  
lieu of central laboratory testing (in the table below), the local laboratory must be 
qualified in accordance with applicable local regulations.  
● Protocol -specific laboratory result  requirements for inclusion or exclusion of 
participants are detailed in Section 5. 
● Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_11006].  
● Investigators must document their review of the laboratory safety results .  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 65 Clinical Laboratory Tests  
Hematology  Clinical Chemistrya 
Hemoglobin  Serum Concentrations of:  
Hematocrit  Sodium  
Erythrocyte count (RBC)  Potassium  
Mean cell volume  Total bilirubin (TBL)  
Mean cell hemoglobin concentration  Direct bilirubin  
Leukocytes (WBC)  Alkaline phosphatase (ALP)  
Neutrophils, segmented  Alanine aminotransferase (ALT)  
Lymphocytes  Aspartate aminotransferase (AST)  
Monocytes  Blood urea nitrogen (BUN)  
Eosinophils  Creatinine  
Basophils  Uric acid  
Platelets  Calcium  
 Glucose  
 Albumin  
Urinalysis  Total cholesterol  
Specific gravity  Creatine kinase (CK)  
pH  
Protein  Pregnancy Test  (females only) b 
Glucose  Serum pregnancy or FSH  
Ketones  Urine pregnancy test (local)  
Blood   
Urine leukocyte esterase c  
  
UDSb  
Abbreviations: FSH = follicle stimulating hormone;  RBC = red blood cells; UDS = urine drug screen; WBC = white 
blood cells.  
a Fasting not required.  
b May be repeated during the study at the discretion of the investigator.  
c A positive urine leukocyte esterase result will require a follow -up sample with microscopic analysis and possibly 
a urine culture.  
 
  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 66 10.5. Appendix 5: Liver Safety: Suggested Actions and Follow -up 
Assessments  
10.5.1.  Hepatic Evalu ation Testing  
See Sections 10.5.[ADDRESS_1014217] bilirubin  
Erythrocytes (RBCs - red blood cells)  Alkaline phosphatase (ALP)  
Leukocytes (WBCs - white blood cells)  Alanine aminotransferase (ALT)  
Differential:  Aspartate aminotransferase (AST)  
    Neutrophils, segmented  Gamma -glutamyl transferase (GGT)  
    Lymphocytes  Creatine kinase (CK)  
    Monocytes  Other Chemistry  
    Basophils  Acetaminophen  
    Eosinophils  Acetaminophen protein adducts  
Platelets  ALP  isoenzymes  
Cell morphology (RBC and WBC)  Ceruloplasmin  
Coagulation  Copper  
Ethyl alcohol (EtOH)  
Prothrombin time, INR (PT -INR)  Haptoglobin  
Serology  Immunoglobulin (Ig)A (quantitative)  
 Hepatitis A virus (HAV) testing:  IgG (quantitative)  
    HAV total antibody  IgM (quantitative)  
    HAV IgM antibody  Phosphatidylethanol (PEth)  
Hepatis B virus (HBV) testing:  Urine Chemistry  
    Hepatitis B surface antigen (HBsAg)  Drug screen  
    Hepatitis B surface antibody (anti -HBs)  Ethyl glucuronide (EtG)  
    Hepatitis B core total antibody (anti -
HBc)  Other Serology  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 67     Hepatitis B core IgM antibody  Anti-nuclear antibody (ANA)  
    Hepatitis B core IgG antibody  Anti-smooth muscle antibody (ASMA)a 
    HBV DNAb Anti-actin antibodyc 
Hepatis C virus (HCV) testing:  Epstein -Barr virus (EBV) testing:  
    HCV antibody      EBV antibody  
    HCV RNAb     EBV DNAb 
Hepatitis D virus (HDV) testing:  Cytomegalovirus (CMV) testing:  
    HDV antibody      CMV antibody  
Hepatitis E virus (HEV) testing:      CMV DNAb 
    HEV IgG antibody  Herpes simplex virus (HSV) testing:  
    HEV IgM antibody      HSV (Type 1 and 2) antibody  
    HEV RNA b     HSV (Type 1 and 2) DNA b 
Microbiology d Liver kidney microsomal type 1 (LKM -1) 
antibody  
Culture:   
    Blood   
    Urine   
a Not required if anti -actin antibody is tested.  
b Reflex/confirmation dependent on regulatory requirements, testing availability, or both.  
c Not required if anti -smooth muscle antibody (ASMA) is tested.  
d Assayed ONLY by [CONTACT_1697] -designated local laboratory; no central testing available.  
10.5.2.  Close Hepatic Monitoring  
Laboratory tests ( Section 10.4), including ALT, AST, ALP, TBL, D. Bil, GGT, and CK, should 
be repeated within 48 to 72 hours to confirm the abnormality and to determin e if it is increasing 
or decreasing, if 1 or more of these conditions occur:  
For participants  enrolled with normal or near normal hepatic biochemical tests  
If a participant with baseline 
results of ...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN  
ALP <1.5x ULN  ALP ≥2x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for participant s with 
Gilbert’s syndrome)  
For participant s enrolled with elevated baseline hepatic biochemical tests  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 68 TBL ≥1.5x ULN  TBL ≥1.5x baseline (except for participant s 
with Gilbert’s syndrome)  
If the abnormality persists or worsens, clinical and laboratory monitoring, and evaluation for 
possible causes of abnormal liver tests should be initiated by [CONTACT_61520] -designated medical monitor. At a minimum, this eva luation should include physical 
examination and a thorough medical history, including symptoms, recent illnesses (for example, 
heart failure, systemic infection, hypotension, or seizures), recent travel, history of concomitant 
medications (including over -the-counter), herbal and dietary supplements, history of alcohol 
drinking and other substance abuse.  
Initially, monitoring of symptoms and hepatic biochemical tests should be done at a frequency of 
1 to 3 times weekly, based on the participant’s clinical c ondition and hepatic biochemical tests. 
Subsequently, the frequency of monitoring may be lowered to once every 1 to 2 weeks, if the 
participant’s clinical condition and laboratory  results stabilize. Monitoring of ALT, AST, ALP, 
and TBL should continue unti l levels normalize or return to approximate baseline levels.  
Comprehensive hepatic evaluation  
A comprehensive evaluation should be performed to search for possible causes of liver injury if 
1 or more of these conditions occur:  
For participant s enrolled wit h normal or near normal hepatic biochemical tests  
If a participant with baseline 
results of...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN with hepatic signs/symptomsa, or  
ALT or AST ≥5x ULN  
ALP <1.5x ULN  ALP ≥3x ULN  
TBL  <1.5x ULN  TBL ≥2x ULN (except for participant s with Gilbert’s 
syndrome)  
For participant s enrolled with elevated baseline  hepatic biochemical tests   
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline with hepatic signs/symptomsa, or 
ALT or AST ≥3x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥2x baseline (except for participant s with Gilbert’s 
syndrome)  
aHepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant 
abdominal pain, fever, rash, and/or eosinophilia >5%.  
At a minimum, this evaluation should include physical examination and a thorough medical 
history, as outlined above, as well as tests for PT -INR; tests for viral hepatitis A, B, C, or E; tests 
for autoimmune hepatitis; and an abdominal imaging study (for e xample, ultrasound or CT scan).  
Based on the participant ’s history and initial results, further testing should be considered in 
consultation with the Lilly -designated medical monitor, including tests for hepatitis D virus 
(HDV), cytomegalovirus (CMV), Eps tein-Barr virus (EBV), acetaminophen levels, 
acetaminophen protein adducts, urine toxicology screen, Wilson’s disease, blood alcohol levels, 
urinary ethyl glucuronide, and blood phosphatidylethanol. Based on the circumstances and the 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 69 investigator’s assessm ent of the participant’s clinical condition, the investigator should consider 
referring the participant for a hepatologist or gastroenterologist consultation, magnetic resonance 
cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatograph y (ERCP), 
cardiac echocardiogram, or a liver biopsy .  
10.5.3.  Additional Hepatic Data Collection ( Hepatic Safety CRF) in Study Participants 
Who Have Abnormal Liver Tests During the Study  
Additional hepatic safety data collection in hepatic safety CRF s should be performed in study 
participants who meet 1 or more of the following 5 conditions:  
1. Elevation of serum ALT to ≥5x ULN on 2 or more consecutive blood tests (if baseline 
ALT <1.5x ULN)  
➢ In participants with baseline ALT ≥1.5x ULN, the threshold is AL T ≥3x baseline 
on 2 or more consecutive tests  
2. Elevated TBL to ≥ 2x  ULN (if baseline TBL <1.5x ULN) (except for cases of known 
Gilbert’s syndrome)  
➢ In participants with baseline TBL ≥1.5x ULN, the threshold should be TBL ≥2x 
baseline  
3. Elevation of serum ALP to ≥2x ULN on 2 or more consecutive blood tests (if baseline 
ALP <1.5x ULN)  
➢ In participants with baseline ALP ≥1.5x ULN, the threshold is ALP ≥2x baseline 
on 2 or more consecutive blood tests  
4. Hepatic event considered to be a n SAE 
5. Discontinuation of study intervention due to a hepatic event  
Note: the interval between the [ADDRESS_1014218] 2 days.  
 
  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 70 10.6. Appendix  6: Provisions for Changes in Study Conduct During 
Exceptional Circumstances  
Implementation of this appendix  
The changes to procedures  described  in this appendix are temporary measures intended to be 
used only during specific time periods  as directed by [CONTACT_741820].  
Exceptional circumstances  
Exceptional  circumstances  are rare events  that may cause disruptions to the conduct of the study.  
Examples include  pandemics or natural disasters.  These disruptions may limit the ability of the 
investigators, participants, or both to attend on -site visits or to conduct planned study procedures.  
Implementi ng changes under exceptional circumstances  
In an exceptional circumstance, after receiving the sponsor’s written approval, sites may 
implement changes if permitted by [CONTACT_427].  
After approval by [CONTACT_31086], regulatory bodies and a ny other relevant local 
authorities, implementation of these exceptional circumstance changes will not typi[INVESTIGATOR_51960], unless they have specific requirements in which 
notification is required (for example, upon im plementation and suspension of changes). All 
approvals and notifications must be retained in the study records.  
If the sponsor grants  written  approval for changes  in study conduct,  the sponsor will also provide  
additional  written  guidance,  if needed.  
Cons iderations for making a change  
The prevailing consideration  for making a change is ensuring the safety of study participants.  
Additional important considerations  for making a change are  compliance with  GCP , enabling  
participants to continue safely in the study  and maintaining the integrity of the study.  
Informed Consent  
Additional consent from the participant will be obtained,  if required,  for:  
 participation in remote visits, as defined  in Section  “Remote  Visits,”  
 alternate  delivery of  study intervention  and ancillary  supplies,  and 
 provision of  their personal  or medical  information  required  prior to implementation of 
these activities.  
Changes in Study Conduct  During  Exceptional Circumstances  
Changes in study conduct not described in this appendix, or not c onsistent with applicable local 
regulations, are not allowed.  
The following changes in study conduct will not be considered protocol deviations.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 71 Remote visits  
Types of remote visits  
Telemedicine:  Telephone or  technology -assisted  virtual visits, or both,  are acceptable  to 
complete  appropriate  assessments.  Assessments to be completed in this manner  include, 
but are not limited to : AE and concomitant medications . 
Mobile healthcare:  Healthcare  visits  may be performed  by a mobile healthcare provider  at 
locations other than the study site  when participants cannot travel to the site  due to  an 
exceptional circumstance  if written  approval is provided by [CONTACT_456].  Procedures 
performed  at such visits  include, but are not limited to : vital signs, 12 -lead ECG , 
collec tion of central laboratory blood and urine samples  including  serum pregnancy, 
collection of MSQ v2.1, MIDAS, and PGI-S via Slate, distribution and collection of the 
ePRO diary and paper headache medication log, and collection of unused study 
interv ention  and ancillary supplies.  
Additionally, procedures listed above as telemedicine may be performed in the  mobile 
healthcare setting . 
Other  alternative locations:  Procedures that may be done  at an alternate location, other 
than listed above,  include  local safety labs, if applicable.   
Data capture  
In source documents and the CRF, the study site should capture the visit method, with a specific 
explanation for any data missing because of missed in -person site visits.  
Safety reporting  
Regardless of the t ype of remote visits implemented, the protocol requirements regarding the 
reporting of AEs, SAEs, and PCs remain unchanged.  
Return to on -site visits  
Every effort should be made to enable participants to return to on -site visits as soon as 
reasonably possi ble, while ensuring the safety of both the participants and the site staff.  
Local laboratory  testing  option  
Local  laboratory testing may be conducted in lieu of central  laboratory  testing . The local 
laboratory must be qualified in accordance with  applicable  local regulations.   
 
Study intervention  and ancillary supplies (including participant diaries)  
When a  participant  is unable to  go to the site to receive  study  supplies  during normal on -site 
visits, the site should work with the sponsor to determ ine appropriate actions.  These actions  may 
include:   
 asking  the participant  to go to the site  and receive  study  supplies  from site staff without 
completion of a  full study  visit,   
 asking  the participant’s  designee to  go to the site  and receive  study  supplies on a  
participant’s  behalf,   
 arranging  delivery  of study supplies,  and  
These  requirements must  be met  before action is taken:  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 72  Alternate  delivery of  study intervention  should be performed in a manner that does not 
compromise treatment blinding and ensures product integrity.  The existing protocol 
requirements for product accountability remain unchanged, including verification of 
participant’s receipt of study supplies.  
 When  delivering supplies to a  location other than the study site (for example,  
participant’s home),  the investigator,  sponsor, or both  should ensure oversight of the 
shippi[INVESTIGATOR_741788] (that is, storage conditions  
maintained  and intact packaging upon receipt).  
 Instructions  may be provided to the participant  or designee  on the final disposition of  any 
unused or  completed  study  supplies.  
Screening period guidance  
To ensure safety of study participants, laboratory values and other eligibility assessments taken 
at the screening visit  are valid for  a maximum of [ADDRESS_1014219] be paused due to 
exceptional circumstances:  
 If screening is paused for 15 days beyond what is allowed for the  screening  period 
(30 days) : the participant will proceed to the next study visit  per the usual SoA, 
provided that Visit [ADDRESS_1014220] the next visit if the participant’s Visit 1 eligibility 
criteria are confirmed, and the site should document the reason for delay.  
o Due to the pause in screening, sites should also reconfirm the impacted 
participant’s consent and document this confirmation in the source 
documentation.  
 If screening is paused for more than 15 days beyond what is allowed for the screening 
period (30 days) : The participant must be discontinued because of screening 
interruption due to an exceptional circumstance. This is documented as a screen 
failure in the CRF. The participant can recons ent and be rescreened as a new 
participant. This rescreen is in addition to the one allowed by [CONTACT_141730].  The 
screening and prospective baseline procedures per the usual SoA should be followed, 
starting at Visit 1 to ensure participant eligibility  or ineligibility  is confirmed by [CONTACT_4838] 
3. 
Adjustments to  Visit Windows  
Whenever possible and safe to do so,  as determined by  [CONTACT_093]’s discretion, participants 
should  complete the usual SoA. To maximize the  possibility that these visits can be conducted as  
on-site visits, the windows  for visits  may be  adjusted,  upon  further  guidance from the  sponsor. 
This minimizes  missing data and preserves  the intended conduct of the study.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 73 This table describes the allowed adjustments to visit windows.  
 
Visit 
Number  Tolerance  
Visits 4 and 5  For telephone assessments only, from the intended date:  
 Up to 2 days prior   
o Participants  should be instructed  to self-
administer  study intervention  prior to telephone 
visit. 
 Up to 7 days after  
o Participants should be instructed to self -
administer study intervention per the original 
schedule.  
Visit 6  For study procedures per SoA from the intended date:  
 Up to 2 days prior  
 Up to 15 days after  
The participant should be instructed to discontinue ODT  as 
per the schedule in normal circumstances  (eg. approximately 
90 days after V isit 3).  
Abbreviation: ECG = electrocardiogram.  
Documentation  
Changes to study conduct will be documented  
Sites will identify and document the details of how participants, visits types, and conducte d 
activities were affected by [CONTACT_52022]. Dispensing/shipment records of study 
intervention and relevant communications, including delegation, should be filed with site study 
records.  
Source documents at alternate locations  
Source documents generated at a location other than the study site should be part of the 
investigator’s  source documentation and should be transferred to the site in a secure and timely 
manner.  
  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 74 10.7. Appendix 7: Abbreviations  and Definitions  
Term  Definition  
AE Adverse event  
ALP Alkaline phosphatase  
ALT Alanine aminotransferase  
ANCOVA  Analysis of covariance  
AST Aspartate aminotransferase  
BCRP  Breast cancer resistant protein  
blinding   A single -blind study is one in which the investigator and/or staff are aware of the treatment 
but the participant is not, or vice versa, or when the sponsor is aware of the treatment but the 
investigator and/his staff and the participant are not.  
A double -blind study is one in which neither the participant nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the subjects are 
aware of the treatment received.  
CEC  Clinical Events Committee  
CGRP  Calcitonin gene -related peptide  
CIOMS  Council  for International  Organizations  of Medical  Sciences  
CK Creatine kinase  
complaint  A complaint is any written, electronic, or oral communication that alleges deficiencies related 
to the identity, quality, purity, durability, reliability, safety or effectiveness, or performance 
of a drug or drug delivery system.  
compliance  Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.  
CRF Case report form  
CTA Clinical Trial Agreement  
CYP Cytochrome P450  
ECG  Electrocardiogram  
eCOA  Electronic Clinical Outcome Assessment  
EDC  Electronic data capture  
enroll  The act of assigning a participant to a treatment. Participants who are enrolled in the study 
are those who have been assigned to a treatment.  
enter  Participants entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 75 ET early termination  
GCP  Good clinical practice  
GGT  Gamma -glutamyl transferase  
GLIMMIX  Generalized linear mixed model  
IB Investigator’s brochure  
ICF Informed consent form  
ICH International Council for Harmonisation  
ICHD  International Classification of Headache Disorders  
IHS International Headache Society  
IMP Investigational Medicinal Product  
informed 
consent  A process by [CONTACT_9444] a participant voluntarily confirms his or her willingness to participate in 
a particular study, after having been informed of all aspects of the study that are relevant to 
the participant’s decision to  participate. Informed consent is documented by [CONTACT_3553] a 
written, signed and dated informed consent form.  
interim analysis  An interim analysis is an analysis of clinical study data, separated into treatment groups, that 
is conducted before the final rep orting database is created/locked.  
INR International normalized ratio  
IRB/IEC  Institutional Review Board/Independent Ethics Committee  
ITT Intention to treat:  The principle that asserts that the effect of a treatment policy can be best 
assessed by [CONTACT_41445] a participant (that is, the planned 
treatment regimen) rather than the actual treatment given. It has the consequence that 
participant allocated to a treatment group should be followed up, assessed, and ana lyzed as 
members of that group irrespective of their compliance to the planned course of treatment.  
IWRS  Interactive web -response system  
LLT Lowest Level Term  
LOCF  Last observation carried forward  
LSMeans  Least Squares Means  
MedDRA  Medical Dictionary for Regulatory Activities  
MMRM  Mixed-model repeated measures  
NIMP  Non-investigational Medicinal Product  
ODT  Oral disintegrating tablet  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 76 participant  Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, either 
as recipi[INVESTIGATOR_10930] a control . 
PC Product complaint  
P-gp P-glycoprotein  
PK/PD  Pharmacokinetics/ Pharmacodynamics  
PPS Per-protocol set:  The set of data generated by [CONTACT_741821], according to the underlying scientific model.  
PRO/ePRO  Patient -reported outcomes/ Electronic patient -reported outcomes  
PT-INR Prothrombin time – international  normalized ratio  
QOD  Every other day  
QTc Corrected QT interval  
QTcF  Fridericia -corrected QT interval  
QTLs  Quality tolerance limits  
SAC  Statistical Analysis Center  
SAE Serious adverse event  
SAP Statistical analysis plan  
SC Subcutaneous  
screen  The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study.  
SMQ  Standardized MedDRA queries  
SIB Suicidal ideation and behavior  
study 
intervention  A pharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical trial, including products already on the market when used or assembled 
(formulated or packaged) in a way different from the authorized form, or markete d products 
used for an unauthorized indication, or marketed products used to gain further information 
about the authorized form.  
TBL Total bilirubin  
TEAE  Treatment -emergent adverse event: An untoward medical occurrence that emerges during a 
defined treat ment period, having been absent pretreatment, or worsens relative to the 
pretreatment state, and does not necessarily have to have a causal relationship with this 
treatment.  
ULN Upper limit of normal  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 77 USPI  [INVESTIGATOR_741789] 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 78 10.8. Appendix 8: Protocol Amendment History  
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).  
Amendment c : (22 -Sep-2022)  
Overall Rationale for the Amendment:  
The purpose of this amendment is to add language regarding an interim analysis with the 
potential for a sample size increase and make minor clarifications.  
Section # and Name  [CONTACT_9353] 1.1 . Synopsis  and Section 
9.5. Sample Size Determination  Original planned 
sample size reduced 
to 575  The sample size was decreased 
to allow for a sample size re -
estimation based on interim 
results that will increase the 
likelihood that the study is 
adequately powered . 
Section 1.3. Schedule of Activities  
(SoA)  Added footnote “c” to 
Serum pregnancy or 
FSH for female 
participants row  Updated to align with current 
internal guidance  
Section 5.1. Inclusion Criteria  In inclusion criterion 
7.b.ii, updated the 
examples of surgical 
sterilization and 
updated definition of 
menopause  Updated the examples of 
surgical sterilization and 
menopause to align with 
current internal guidance  
Section 5.2. Exclusion Criteria  In exclu sion criterion 
10: deleted “multiple 
drugs”  Risk was discharged in 
previous  clinical trials. History 
of hypersensitivity to “multiple  
drugs” does not pose a safety 
risk for use of galcanezumab . 
Section 6.3. Measures to Minimize 
Bias: Randomization and Bli nding  Updated guidance on 
self-injections during 
telephone visits  To clarify the timing of 
telephone visit with regards to 
the injection of study 
intervention  
Section 6.4. Study Intervention 
Compliance  Updated text 
regarding the return of 
unused study 
intervention  To provide flexibility in the 
type of closed container the 
participants may use to return 
unused study drug  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 79 Section # and Name  [CONTACT_9353] 7.1.1. Liver Chemistry 
Stoppi[INVESTIGATOR_741790] 9.3.2. Primary 
Endpoint(s)/Estimand(s) Analysis  Added language 
regarding an interim 
analysis with the 
potential for a sample 
size increase  and 
language regarding 
potential sample size 
increas e Addition  
Section 9.3.3. Secondary 
Endpoints/Estimands Analysis  Added sentence 
regarding sample size 
and CHW test  Clarity  
Section 9.3.4. Safety Analyses  Removed “potential 
hypersensitivity 
events”  Correction  
Section 9.4. Interim Analysis  Added language 
regarding an interim 
analysis  Addition  
Section 10.1.4. Committees 
Structure  Added “resuscitated 
cardiac arrest”  Addition to match finalized 
CEC charter  
Section 10.2 . Appendix 2: 
Treatments Allowed and 
Treatments not Allowed as 
Concomitant Therap y Added footnotes “a ,” 
“b,” “c,” and “d” 
under Appendix 2 
table; added 
Migravent, 
desvenlafaxine, and 
Paxlovid to table  Clarification for medications 
not allowed during SP II and III  
Throughout  Other minor editorial 
changes  Minor therefore not described  
Amendment b: (18 -Feb-2022)  
Overall Rationale for the Amendment:  
The purpose of this amendment is to update SAE/pregnancy reporting via paper forms and make 
minor clarifications for sites and consistency within the document.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 80 Section # and Name  [CONTACT_62578] o f Change  Brief Rationale  
1.2 Schema  Clarified footnotes within 
the schema and added 
placebo to each study 
intervention.  Minor change added for clarity.  
1.2 Schema; 1.3 
Schedule of 
Activities (SoA)  Clarified that investigators 
have up to 5 additional days 
if needed to schedule 
participant’s Visit 3 
appointment.  Minor clarification added for clarity and 
added additional flexibility for sites and 
participants.  
1.3 Schedule of 
Activities (SoA)  Removed neurological 
examination for Visit 6 and 
early termin ation.  Based on established safety profiles for 
the study interventions, assessment is not 
required  
1.3 Schedule of 
Activities (SoA); 
10.4 Appendix 4: 
Clinical Laboratory 
Tests  Separated urine drug screen  
from urinalysis, clarified 
UDS is not required fo r 
Visit [ADDRESS_1014221] be negative 
at or prior to Visit 2.  Corrected from previous protocol 
versions.  
1.3 Schedule of 
Activities (SoA)  Clarified the headache 
medication log should be 
returned to site staff at th e 
final office visit or early 
termination visit.  Minor clarification.  
1.3 Schedule of 
Activities (SoA)  Moved both participant 
training videos lines so they 
are together and clarified 
videos may be viewed at 
either Visit 2 or Visit 3.  Minor clarification added for additional 
flexibility for sites and participants.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 81 Section # and Name  [CONTACT_62578] o f Change  Brief Rationale  
4.1.1 Study Period 
I: Screening (Visit 
1); 4.1.2 Study 
Period II: 
Prospective 
Baseline (Visit 2); 
4.1.3 Study Period 
III: Double -Blind 
Treatment (Visits 
3-6) Sections were r e-formatted.  Minor changes for clarity.  
4.1.2 Study Period 
II: Prospective 
Baseline (Visit 2)  Clarified timing of initial 
study intervention shipment 
and eligibility.  Clarified for sites.  
5.1 Inclusion 
Criteria  Changed age to 18 to 75 
years of age (incl usive) in 
Inclusion Criterion #1.  Changed to include older patients 
consistent with recent studies for 
galcanezumab.  
5.2 Exclusion 
Criteria  Removed “significant 
active or unstable” when 
describing psychiatric 
disease by [CONTACT_9870].  Minor clarification.  
5.2 Exclusion 
Criteria  Removed Exclusion 
Criterion #19.  Changed to be consistent with recent 
studies for galcanezumab.  
5.2 Exclusion 
Criteria  Revised Exclusion 
Criterion #[ADDRESS_1014222] used 
opi[INVESTIGATOR_741791] >[ADDRESS_1014223] 3 months.  Changed to be consistent with recent 
studies for galcanezumab.  
5.2 Exclusion 
Criteria  Added exceptions to a 
positive UDS for 
benzodiazepi[INVESTIGATOR_741792] #23.  Clarified to keep consistent with 
permitted concomitant medications.  
5.2 Exclusion 
Criteria  Updated ophthalmoplegic 
to retinal migraine in 
Exclusion Criterion #26.  To align with current guidance.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 82 Section # and Name  [CONTACT_62578] o f Change  Brief Rationale  
5.2 Exclusion 
Criteria  Added Exclusion Criterion 
#33 to exclude participants 
with a history of ≥[ADDRESS_1014224] 3 months or 
are suspected of suffering 
from chronic migraine as 
defined per IHS ICHD -3. To clarify exclusion criteria related to 
chronic migraine.  
5.4 Screen Failures  Added rescreen allowance 
for Exclusion Criterion #16 
which excludes patients 
with an acute, serious, or 
unstable medical condition 
that in the judgement of the 
investigator precludes study 
participation.  This change allows for participants to 
rescreen if their acute or unstable illness 
resolves and/or is controlled.  
5.[ADDRESS_1014225] become eligible 
to enroll in the study as a 
result of a protocol 
amendment.  Clarification.  
6.3 Measures to  
Minimize Bias: 
Randomization and 
Blinding  Clarified in the case of 
emergency unblinding that 
if a participant’s 
intervention assignment is 
unblinded, the sponsor must 
be notified immediately 
after breaking the blind.  Clarification.  
6.8 Concomitant 
Therap y Clarified that botulinum 
toxin A or B in the head or 
neck area for therapeutic 
use is not allowed within 4 
months prior to Visit 2.  Corrected error.  
7.1 Discontinuation 
of Study 
Intervention  Clarified if study 
intervention is permanently 
discontinued, the 
participant should remain in 
the study to be evaluated 
for safety and efficacy 
assessments, unless criteria 
in Section 7.2 apply.  Minor clarification.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 83 Section # and Name  [CONTACT_62578] o f Change  Brief Rationale  
8.2.[ADDRESS_1014226] 
Complaints; 8.3.[ADDRESS_1014227] 
Complaints; [IP_ADDRESS] 
Time Period for 
Detecting Product 
Complaints; [IP_ADDRESS] 
Follow-Up of 
Product Complaints  Moved text from Section 
8.3.2, Section [IP_ADDRESS], and 
Section [IP_ADDRESS] into Section 
8.3. Minor changes for clarity.  
8.3.1 Timing and 
Mechanism for 
Collecting Events; 
10.3.3 Recording 
and Follow -Up of 
AE and/or SAE  Clarified the me chanism for 
reporting adverse events as 
the AE CRF, severe adverse 
events as the SAE paper 
form, and pregnancy as the 
pregnancy paper form.  Electronic methods are not used for this 
study.  
10.1.4 Committees 
Structure  Updated text to include 
terms and event s for 
adjudication.  Minor changes for clarity.  
10.2 Appendix 2: 
Treatments 
Allowed and 
Treatments not 
Allowed as 
Concomitant 
Therapy  Clarified opi[INVESTIGATOR_741793] 4 days /month.  Clarified for flexibility.  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 84 Section # and Name  [CONTACT_62578] o f Change  Brief Rationale  
10.2 Appendix 2: 
Treatments 
Allowed and 
Treatments not 
Allowed as 
Concomitant 
Therapy  Clarified gabapentin, 
pregabalin, and stimulants 
(prescription strength) are 
restricted during SP II and 
III and may be used for 
indications other than 
migraine prevention 
provided the do se is stable 
2 months prior to Visit 2 
and is expected to remain 
stable during Visit 2 
through 6.  Changed to be consistent with recent 
studies for galcanezumab.  
10.3.3 Recording 
and Follow -Up of 
AE and/or SAE  Removed “product 
complaint” and clarified 
CRF.  To ensure consistency with protocol text.  
10.3.4 Reporting of 
SAEs  Removed section for SAE 
reporting via an electronic 
data collection tool.  Not applicable to study.  
10.3.4 Reporting of 
SAEs  Clarified facsimile 
transmission of the SAE 
paper form to the  sponsor 
or designee.  Align with changes made throughout the 
protocol.  
10.6 Appendix 6: 
Provisions for 
Changes in Study 
Conduct During 
Exceptional 
Circumstances  Clarified telemedicine and 
mobile healthcare example 
assessments.  Minor clarification.  
10.6 Appendix 6: 
Provisions for 
Changes in Study 
Conduct During 
Exceptional 
Circumstances  Clarified at visit windows 
when participants should be 
instructed to self -administer 
study intervention and 
discontinue ODT.  Minor clarification.  
Throughout  Reference to Manual of 
Operations was changed to 
Reference Manual.  Align with current manual.  
Throughout  Other minor editorial 
changes were made to add 
clarity.  Minor therefore not described.  
 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 85 Amendment a: (6 -Aug-2021)  
Overall Rationale for the Amendment:  
The current sample size and power estimates assume a scenario where the reduction in migraine 
days across Months 1, 2, and 3 for rimegepant in the current study will be consistent with the 
reduction in migraine days at Month 3 for rimegepant as published for t heir single phase 2/3 
prevention study. The proposed sample size increase to approximately 700 randomized patients 
assumes a smaller reduction in migraine days with rimegepant during Months 1 and 2 compared 
to Month 3.  
Section # and Name  [CONTACT_741823].  
1.1. Synopsis  
9.5. Sample Size 
Determination  Increased sample size and 
updated sample size 
determination.  Additional power to detect effect.  
6. Study 
Intervention(s) and 
Concomitant 
Therapy  Added additional definition 
for “study intervention”.  Clarification.  
Throughout  Minor editorial corrections.  Minor therefore not described.  
 
 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 86 11. References  
[AHS] American Headache Society. The American Headache Society position statement on 
integrating new migraine treatments into clinical practice. Headache . 2019;59(1):1 -18. 
https://doi.org/ 10.1111/head.[ZIP_CODE]  
Bagley CL, Rendas -Baum R, Maglinte GA, et al. Validating migraine -specific quality of life 
questionnaire  v2.1 in epi[INVESTIGATOR_33176]. Headache . 2012;52(3):409 -421. 
https://doi.org/10.1111/j.[ADDRESS_1014228] confidence bounds following adaptive group sequential 
tests. Biometrics . 2009;65(2):539 -546. https://doi.org/ 10.1111/j.1541 -0420.2008.[ZIP_CODE]. x 
Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among 
chronic and epi[INVESTIGATOR_160343]: results from the International Burden of Migraine Study 
(IBMS). Cephalalgia . 2011;31(3):301 -315. https://doi.org/ 10.1177/033310241038114 5 
Brain  SD, Williams TJ, Tippi[INVESTIGATOR_289318],  et al. Calcitonin gene -related peptide is a potent vasodilator. 
Nature.  1985 ;313( 5997 ):54-56. https://doi.org/ 10.1038/313054a0  
Charles A, Pozo -Rosich P. Targeting calcitonin gene -related peptide: a new era in migraine 
therapy. Lancet . 2019;394([ZIP_CODE]):1765 -1774. 
https://doi.org/ 10.1016/S0140 -6736(19)[ZIP_CODE] -8 
Chiang C, Schwedt TJ. Calcitonin gene -related peptide (CGRP) -targeted thera pi[INVESTIGATOR_741794] -The monoclonal antibodies and gepants. Prog Brain Res . 
2020;255:143 -170. https://doi.org/ 10.1016/bs.pbr.2020.06.019  
Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migrai ne: a 
phase 2/3, randomised, double -blind, placebo -controlled trial. Lancet . 2021;397([ZIP_CODE]):51 -60. 
https://doi.org/10.1016/S0140 -6736(20)[ZIP_CODE] -7 
Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical trials.  
Biometrics . 1999;55(3):853 -857. https://doi.org/ 10.1111/j.0006 -341x.1999.[ZIP_CODE].x  
Dodick DW, Goadsby [CONTACT_33263], Spi[INVESTIGATOR_142886], et al. Safety and efficacy of LY2951742, a 
monoclonal antibody to calcitonin gene -related peptide, for the prevention of migraine: a 
phase 2, randomi sed, double -blind, placebo -controlled study. Lancet Neurol . 2014a;13(9):885 -
892. https://doi.org/10.1016/S1474 -4422(14)[ZIP_CODE] -0 
Dodick DW, Goadsby [CONTACT_33263], Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to 
calcitonin gene -related peptide, for the prevention of frequent epi[INVESTIGATOR_17730]: a 
randomised, double -blind, placebo -controlled, exploratory phase 2 trial. Lancet Neurol . 
2014b;13(11):1100 -1107.  https://doi.org/10.1016/S1474 -4422(14)[ZIP_CODE] -1 
Emgality [package insert].  Indianapolis, IN:  Eli L illy and Company ; 2019.  
[FDA ] Guidance for Industry: Drug -Induced Liver Injury: Premarketing Clinical Evaluation, 
July 2009 . Accessed 1 May 2021. https://www.fda.gov/media/116737/download  
[FDA] E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R 1). March 2018. 
Accessed Aug ust 01, 2021. https://www.fda.gov/media/[ZIP_CODE]/download  
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 87 Goadsby [CONTACT_33263], Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation 
of humans during migraine headache. Ann Neurol . 1990;28(2):183 -187. 
https://doi.org/10.1002/ana.410280213  
Goadsby [CONTACT_33263], Edvinsson L. The trigeminovascular system and migraine: studies characterizing 
cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol . 
1993;33(1):48 -56. https://doi.org/ 10.1002/ana.41 0330109  
Guy W. ECDEU assessment manual for psychopharmacology, revised 1976. Rockville, MD: 
National Institute of Mental Health, Psychopharmacology Research Branch. P 217 -222. 
Accessed September 29, 2014. https://archive .org/details/ecdeuassessmentm1933guy w 
Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene -related peptide triggers migraine -
like attacks in patients with migraine with aura. Cephalalgia.  2010;30(10):1179 -1186. 
https://doi.org/ 10.1177/[ADDRESS_1014229] BIBN4096BS peripherally 
alleviates inflammatory pain in rats. Pain . 2013;154(5):700 -707. 
https://doi.org/ 10.1016/j.pain.2013.01.002  
[ICHD -3] Headache Classification Committee of the International Headache Society (IHS). The 
International Classification of Headache Disorders, 3rd edition. Cephalalgia . 2018;38(1):1 -
211. https://doi.org/10.1177/0333102417738202  
Jhingran P, Davis SM, LaVange LM, et al. MSQ: Migraine -Specific Quality -of-Life 
Questionnaire. Further investigation of the factor structure. Pharmacoeconomics . 
1998a;13(6):707 -717. https://doi.org/ 10.2165/00019053 -199813060 -[ZIP_CODE]  
Jhingran P, Osterhaus JT, Miller DW, et al. Development and validation of the Migraine -
Specific Quality of Life Questionnaire. Headache . 1998b;38(4):295 -302. 
https://doi.org/10.1046/j.1526 -4610.[PHONE_15476].x  
Juhasz G, Zsombok T, Modos EA, et al. NO -induced migraine attack: strong increase in plasma 
calcitonin gene -related peptide (CGRP) concentration and negative correlation with platelet 
serotonin release. Pain.  2003;106(3):461 -470. https://doi.org/ 10.1016/j.pain.2003.09.008  
Juhasz G, Zsombok T, Jakab B, et al. Sumatriptan causes parallel decrease in plasma calcitonin 
gene -related peptide (CGRP) concentration and migraine headache during n itroglycerin 
induced migraine attack. Cephalalgia . 2005;25 (3):179-183. https://doi.org/ 10.1111/j.[ADDRESS_1014230] of 
galcanezumab for prevention of migraine: a narrative review of three randomized placebo -
controlled trials. Adv Ther . 2021;38(3):1614 -1626. https://doi.org/ 10.1007/s12325 -021-[ZIP_CODE] -
x 
Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. 
Cephalalgia . 2002;22(1):54 -61. https://doi.org/ 10.1046/j.1468 -2982.2002.[ZIP_CODE].x  
Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the 
impact on people ’s life. J Headache Pain.  2019;20(1):41. https://doi.org/ 10.1186/s10194 -019-
0993 -0 
Approved on 02 Nov 2022 GMT
CONFIDENTIAL  Protocol number I5Q -MC-CGBD (d) 
 88 Lipton RB, Silber stein SD. Epi[INVESTIGATOR_65899]: breaking down barriers to 
optimal treatment and prevention.  Headache . 2015;55(suppl 2):103 -122. 
https://doi.org/ 10.1111/head.12505_2  
Martin BC, Pathak DS, Sharfman MI, et al. Validity and reliability of the  Migraine -Specific 
Quality of Life Questionnaire (MSQ Version 2.1). Headache . 2000;40(3):204 -215. 
https://doi.org/ 10.1046/j.1526 -4610.2000.[ZIP_CODE].x  
Nurtec [package insert] . New Haven, CT : Biohaven Pharmaceutical s, Inc .; 2021.  
Silberstein SD, Holland S, Freitag F, et al.; Quality Standards Subcommittee of the American 
Academy of Neurology and the American Headache Society.  Evidence -based guideline 
update: pharmacologic treatment for epi[INVESTIGATOR_33215]: report of the 
Quality Standards S ubcommittee of the American Academy of Neurology and the American 
Headache Society . Neurology . 2012;78(17):1337 -1345. 
https://doi.org/ 10.1212/WNL.0b013e3182535d20  
Schwedt T, Reuter U, Tepper S,  et al. Early onset of efficacy with erenumab in patients with 
epi[INVESTIGATOR_33176]. J Headache Pain . 2018;19(1):92 . 
https://doi.org/ 10.1186/s10194 -018-0923 -6 
Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the 
prevention of epi[INVESTIGATOR_17730]: results of the EVOLVE -2 Phase 3 randomized controlled 
clinical trial. Cephalalgia.  2018;38(8):1442 -1454. https://doi.org/ 10.1177/0333102418779543  
Stauffer VL, Dodick DW, Zhang Qi, et al. Evaluation of galcanezumab for the prevention of 
epi[INVESTIGATOR_17730]: the EVOLVE -1 randomized clinical trial. JAMA Neurol.  2018;75(9):1080 -
1088. https://doi.org/ 10.1001/jamaneurol.2018.1212  
Stewart WF, Lipton RB, Whyte J, et al. An international study to assess reliability of the 
Migraine Disability Assessment (MIDAS) score. Neurology . 1999a;53(5):9 88-994. 
https://doi.org/ 10.1212/wnl.53.5.988  
Stewart WF, Lipton RB, Kolodner K, et al. Reliability of the migraine disability assessment 
score in a population -based sample of headache sufferers. Cephalalgia . 1999b;19(2):107 -114. 
https://doi.org/ 10.1046/j.1 468-2982.1999.019002107.x  
Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine 
Disability Assessment (MIDAS) Questionnaire to assess headache -related disability (abstract). 
Neurology . 2001;56([ADDRESS_1014231] 1):S20 -S28. https://doi.o rg/10.1212/wnl.56.suppl_1.s20  
Vos T, Abajobir A, Abbafati C, et al. Global, regional, and national incidence, prevalence, and 
years lived with disability for 328 diseases and injuries for 195 countries, 1990 -2016: a 
systematic analysis for the Global Burde n of Disease Study 2016.  Lancet . 
2017 ;390([ZIP_CODE]):1211 -1259. https://doi.org/ 10.1016/S0140 -6736(17)[ZIP_CODE] -2 
Approved on 02 Nov 2022 GMT
Signature [CONTACT_11032]-CLIN-075435 v1.0
Signature [CONTACT_11032]-CLIN-075435 v1.0Approval
Medical Director
02-Nov-2022 12:53:37 GMT[PHONE_006]
Approval
Statistician
02-Nov-2022 16:41:47 GMT[PHONE_006]
Approved on 02 Nov 2022 GMT
[COMPANY_003]
[COMPANY_003]